picture
RJR-logo

About | BLOGS | Portfolio | Misc | Recommended | What's New | What's Hot

About | BLOGS | Portfolio | Misc | Recommended | What's New | What's Hot

icon

Bibliography Options Menu

icon
QUERY RUN:
18 Nov 2026 at 01:37
HITS:
52354
PAGE OPTIONS:
Hide Abstracts   |   Hide Additional Links
NOTE:
Long bibliographies are displayed in blocks of 100 citations at a time. At the end of each block there is an option to load the next block.

Bibliography on: Alzheimer Disease — Current Literature

RJR-3x

Robert J. Robbins is a biologist, an educator, a science administrator, a publisher, an information technologist, and an IT leader and manager who specializes in advancing biomedical knowledge and supporting education through the application of information technology. More About:  RJR | OUR TEAM | OUR SERVICES | THIS WEBSITE

RJR: Recommended Bibliography 18 Nov 2026 at 01:37 Created: 

Alzheimer Disease — Current Literature

Alzheimer's disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. In most people with Alzheimer's, symptoms first appear in their mid-60s. Alzheimer's is the most common cause of dementia among older adults. Dementia is the loss of cognitive functioning — thinking, remembering, and reasoning — and behavioral abilities to such an extent that it interferes with a person's daily life and activities. Dementia ranges in severity from the mildest stage, when it is just beginning to affect a person's functioning, to the most severe stage, when the person must depend completely on others for basic activities of daily living. Scientists don't yet fully understand what causes Alzheimer's disease in most people. There is a genetic component to some cases of early-onset Alzheimer's disease. Late-onset Alzheimer's arises from a complex series of brain changes that occur over decades. The causes probably include a combination of genetic, environmental, and lifestyle factors. The importance of any one of these factors in increasing or decreasing the risk of developing Alzheimer's may differ from person to person. This bibliography runs a generic query on "Alzheimer" and then restricts the results to papers published in or after 2017.

Created with PubMed® Query: 2024:2026[dp] AND ( alzheimer*[TIAB] ) NOT pmcbook NOT ispreviousversion

Citations The Papers (from PubMed®)

-->

RevDate: 2026-11-16

Mengr A, Sopko Z, Vaculová P, et al (2026)

Metabolic, Hepatic, and Neuropathological Effects of Palm[11]-PrRP31 and Liraglutide in High-Fat Diet-Fed APP/PS1 Mice.

Neuropharmacology pii:S0028-3908(26)00438-7 [Epub ahead of print].

Metabolic stress is known to accelerate Alzheimer's disease (AD) progression. In our previous study, we demonstrated that long-term high-fat diet (HFD) feeding exacerbated not only amyloid-β (Aβ) burden but also liver steatosis in APP/PS1 mice, a transgenic model of AD, with effects worsening with age. The present study investigated whether a three-month treatment (from 6 to 9 months of age) with anorexigenic peptides (palm[11]-PrRP31 or liraglutide) could attenuate AD-like pathology, neuroinflammation, liver steatosis, and Aβ clearance in APP/PS1 male mice on HFD. The two compounds exhibited distinct therapeutic effects. Liraglutide reduced body weight and improved glucose tolerance in both genotypes, while also attenuating insulin resistance in APP/PS1 mice. In contrast, palm[11]-PrRP31 significantly reduced Aβ plaque burden and showed a tendency to decrease astrocytosis. Notably, both peptides markedly reduced microgliosis and pathological tau phosphorylation at Ser202 and Thr205 in the hippocampus and cerebral cortex. HFD induced pronounced hepatic steatosis in both genotypes; however, APP/PS1 mice exhibited more severe lipid imbalance, characterized by increased triacylglycerols and decreased phospholipids and cardiolipins compared to wild-type controls. While both compounds reduced liver steatosis and inflammation in wild-type mice, only liraglutide normalized lipid composition in APP/PS1 mice. Furthermore, Aβ deposits colocalized with CD11b clusters were absent in the liver of liraglutide-treated APP/PS1 mice. In conclusion, both peptides exert neuroprotective effects under metabolic stress, but through distinct mechanisms. Palm[11]-PrRP31 primarily reduces amyloid pathology and neuroinflammation, whereas liraglutide acts mainly through metabolic improvement.

RevDate: 2026-11-16

Roberts KF, Abrams ZB, Cappelletti L, et al (2026)

An open agentic AI co-scientist for clinical and biomedical discovery.

Nature medicine pii:10.1038/s41591-026-04808-6 [Epub ahead of print].

Biomedical research is constrained by the time and domain expertise required to analyze increasingly large and complex datasets. Here we present OpenScientist, an open-source agentic AI co-scientist designed to address this gap by investigating scientist-defined queries and generating verifiable, data-grounded analyses. OpenScientist was evaluated by domain experts across five biomedical case studies, completing analyses in minutes that otherwise would take months of human time and expertise. It accurately quantified Alzheimer's blood biomarker performance, generated a plasma proteomic survival model that predicted survival in a hidden-evaluation cohort, proposed a reproducible mechanism linking tau pathology to altered lysosomal acidification, generated multiple myeloma hypotheses validated in an external cohort with attenuated signal in randomized controls, and demonstrated concordance with an independent human analysis in a blinded, prespecified proteomic comparison. These results support the use of OpenScientist to assist biomedical data analysis in concert with human experts. To support research involving sensitive clinical datasets, OpenScientist can operate in a fully air-gapped environment using open-source models for inference. OpenScientist demonstrates that open, auditable, agentic AI can support real-world clinical research by researching the literature, generating hypotheses, executing analyses, and generating insights from complex datasets.

RevDate: 2026-11-16

Yang Y, Wen J, J Zhou (2026)

Advancing Advance Care Planning for Dementia: From Stakeholder Participation to Sustained, Preference-Concordant Care.

RevDate: 2026-11-16

Rouch L, Middleton L, Aisen P, et al (2026)

Advancing the Alzheimer's disease research and care pipeline with agentic artificial intelligence: Opportunities, challenges, and priorities from the international clinical trials on Alzheimer's disease (CTAD) task force.

The journal of prevention of Alzheimer's disease pii:S2274-5807(26)00201-3 [Epub ahead of print].

Artificial Intelligence (AI) holds unprecedented potential to transform the entire Alzheimer's Disease and related dementias (ADRD) research and care continuum. During the 2025 Clinical Trials on Alzheimer's Disease (CTAD) conference, the CTAD Task Force reviewed recent advances in the field, highlighting the emerging role of agentic AI, and discussed priorities to guide future AI-driven innovation in ADRD. Agentic AI co-scientists are emerging as transformative tools to accelerate scientific discovery by autonomously integrating multimodal data, generating and evaluating new hypotheses, and connecting previously siloed knowledge into actionable insights. Operationalized through end-to-end translational pipelines, such platforms can also link mechanistic insights to therapeutic design by automating molecular docking and drug repurposing. Complementary initiatives are creating digital wet labs for in silico experimentation. At the same time, agentic AI is increasingly being used to address pre-discovery bottlenecks by automating data harmonization and inferring missing information through digital twins and synthetic data. AI is also reshaping next-generation ADRD clinical trials, through automated assessment of clinical outcomes, precision participant stratification, individualized disease trajectory modeling and prediction of treatment response. These approaches could substantially improve trial efficiency through responder enrichment. Importantly, AI applications are expanding beyond discovery and clinical trials to support diagnosis, care navigation, and personalized disease management. To translate the momentum surrounding AI innovation into meaningful and sustainable impact across the ADRD continuum, the Task Force identified priorities including the development of AI-ready ecosystems, closer collaboration between clinicians, researchers and computer scientists, AI-enabled optimization of clinical trials and robust ethical and governance frameworks for responsible AI adoption.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Liu H, Liu Y, Li W, et al (2026)

[Mechanism of acupuncture at governor vessel acupoints in improving cognitive dysfunction in AD mice based on complement C1q-mediated microglial synaptic phagocytosis].

Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 46(11):1802-1808.

OBJECTIVE: To explore the possible mechanism of acupuncture at governor vessel (GV) acupoints in improving cognitive dysfunction in Alzheimer's disease (AD) mice based on complement C1q-mediated aberrant activation of microglia and excessive synaptic phagocytosis.

METHODS: Twenty male APP/PS1 double transgenic mice were randomly divided into a model group and an acupuncture group, with 10 mice in each group; ten male C57BL/6 mice were selected as the control group. In the acupuncture group, acupuncture was applied at "Baihui" (GV20), "Dazhui" (GV14) and "Mingmen" (GV4), 20 min each time, once daily, 5 times a week for 4 consecutive weeks. The learning-memory ability of mice was assessed by Morris water maze test, the synaptic ultrastructure in hippocampal CA1 region was observed by transmission electron microscope, the positive expression of postsynaptic density protein 95 (PSD-95) and ionized calcium-binding adapter molecule 1 (IBA-1) in hippocampal tissue was detected by immunofluorescence, the protein expression of IBA-1, complement C1q and SMAD-specific E3 ubiquitin protein ligase 1 (SMURF1) in hippocampal tissue was detected by Western blot, the ubiquitination modification of C1q protein was predicted by UbiBrowser and further verified by co-immunoprecipitation (Co-IP).

RESULTS: Compared with the control group, in the model group, the escape latency was prolonged (P<0.01), the number of platform crossings was reduced (P<0.01); decreased number of synapses, damaged synaptic structure, and thinner and looser postsynaptic density could be observed in the hippocampal CA1 region; the positive expression of IBA-1 and the protein expression of C1q and IBA-1 were increased (P<0.01), the positive expression of PSD-95 and the protein expression of SMURF1 were decreased (P<0.01) in hippocampal tissue. Compared with the model group, in the acupuncture group, the escape latency was shortened (P<0.05), the number of platform crossings was increased (P<0.05); increased number of synapses, improved synaptic structure, and thicker and denser postsynaptic density could be observed in hippocampal CA1 region; the positive expression of IBA-1 and the protein expression of C1q and IBA-1 were decreased (P<0.01, P<0.05), the positive expression of PSD-95 and the protein expression of SMURF1 were increased (P<0.01, P<0.05) in hippocampal tissue. SMURF1 was identified as the E3 ligase for C1q protein, and SMURF1 could bind to C1q.

CONCLUSION: Acupuncture at GV acupoints directly or indirectly reduces C1q level in the hippocampus, inhibits the classical complement system and excessive microglial activation, reduces aberrant synaptic phagocytosis, and thereby improves cognitive dysfunction in AD mice.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Rousset RZ, den Braber A, Bongers B, et al (2026)

APOE ε4 carriership status enhances age-related changes in Alzheimer's disease plasma biomarkers concentrations.

Nature communications, 17(1):.

Alzheimer's disease (AD) plasma biomarkers are cost-effective tools to detect early stage amyloid pathology. We investigated how interactions between AD genetic risk (apolipoprotein E (APOE) ε4, AD polygenic risk score (excluding APOE; PRSAD)), age, and sex affected AD plasma biomarkers concentrations in a population-based cohort. We included 5913 participants from the Netherlands Twin Register age 30 - 80 (64.1% females, 29.8% ε4 carriers) and measured plasma phosphorylated-tau-217 (p-tau217), amyloid-β-42/40 (Aβ-42/40), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP). We showed that the PRSAD did not associate with biomarker concentrations over age. In ε4 carriers, decreases in Aβ-42/40 became steeper after age 50, and increases in p-tau217 and GFAP became steeper after age 55 and 60 compared to non-carriers, respectively. Analyses in a separate longitudinal cohort (EMIF-AD) confirmed that p-tau217 concentration changes in ε4 carriers reflect AD pathology. These results highlight the potential of plasma biomarkers, especially p-tau217, for early detection of preclinical AD pathology.

RevDate: 2026-11-16
CmpDate: 2026-11-17

Melcher EM, Otte RC, Lim S, et al (2026)

Association of life-course production work and Lewy body neuropathology.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.

INTRODUCTION: The occupational exposome-the summation of lifetime workplace exposures-impacts Alzheimer's disease and related dementias (ADRD). Examining the role of high-risk occupational exposures on ADRD pathology, including Lewy bodies, may enable disease mitigation strategies.

METHODS: This retrospective cohort study included brain donors with neuropathological characterization (n = 1079, 47.5% female, mean age at death: 80.9). Donor occupational histories were derived and assigned Standardized Occupation Classification Codes. The association between Lewy body neuropathology and "production occupations" (i.e., assemblers, fabricators, manufacturers, etc.) was modeled via logistic regression adjusting for age, sex, and year of death.

RESULTS: Lewy bodies were present in 32% of the total sample. Donors with a history of "production occupations" (12%) had 23% increased adjusted odds of having Lewy bodies (adjusted odds ratio = 1.23, 95% confidence interval = 1.11-1.35).

DISCUSSION: This is the first study demonstrating increased levels of Lewy body neuropathology in those with "production occupations." Precise categorization of hazardous exposures is needed to identify mechanistic pathways.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Arshad F, Tripathi PP, Shetye N, et al (2026)

Diagnostic performance of blood-based biomarker thresholds and ratios across the cognitive continuum in a diverse South Asian cohort.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 22(11):.

INTRODUCTION: The rising burden of dementia in the Global South is compounded by a substantial diagnostic gap limiting access to biomarker-based diagnosis. We evaluated the diagnostic performance of non-invasive blood-based biomarkers and their ratios across the cognitive continuum in a South Asian cohort to address a lack of evidence beyond Western populations.

METHODS: This study included participants from a Cognitive Disorders Clinic (n = 315), comprising individuals with mild cognitive impairment (MCI), Alzheimer's disease (AD), frontotemporal dementia (FTD), and cognitively unimpaired (CU) controls. All participants underwent standardized cognitive assessment and structural brain imaging. Serum phosphorylated tau (p-tau217), p-tau181, and neurofilament light (NfL) were quantified using a Simoa HD-X analyzer. Diagnostic performance of biomarkers and their ratios were assessed, and a novel multi-threshold approach was applied to facilitate their clinical interpretation in routine practice.

RESULTS: Serum p-tau217 and NfL levels were significantly higher in the cognitively impaired group compared to CU, whereas p-tau181 showed no significant difference. Across the diagnostic groups, p-tau217 was highest in AD (F = 12.61, p < 0.001), and NfL in FTD (F = 20.84, p < 0.001). NfL best discriminated FTD versus CU, whereas p-tau217 showed optimal discrimination for AD (area under the curve [AUC] = 0.85). The NfL/p-tau217 ratio improved discrimination between AD and FTD (AUC = 0.78). The multi-threshold approach demonstrated superior diagnostic performance compared to single cut-off.

DISCUSSION: Serum p-tau217, NfL, and NfL/p-tau217 ratio showed robust diagnostic accuracy in this diverse South Asian cohort. The multi-threshold approach improved the clinical interpretability, supporting the integration of blood-based biomarkers (BBMs) in clinical practice, enabling timely diagnosis and accurate determination of therapeutic eligibility.

RevDate: 2026-11-17

Anonymous (2026)

Two new blood tests for Alzheimer's disease.

The Medical letter on drugs and therapeutics, 68(1768):185-186.

RevDate: 2026-11-17

Zou S, Li L, Xiang W, et al (2026)

Integrative computational and in-vitro evidence implicates BCL2-associated apoptotic signaling in acetyl tributyl citrate-induced microglial toxicity.

Drug and chemical toxicology [Epub ahead of print].

Acetyl tributyl citrate (ATBC), a synthetic plasticizer, exhibits neurotoxic potential. Microglia sustain brain homeostasis, and their apoptosis and dysfunction are key drivers of Alzheimer's disease (AD) pathogenesis. However, the mechanism connecting ATBC exposure to microglial impairment and AD susceptibility remains unclear. Here, we applied an integrative computational and in-vitro framework to investigate BCL2-centered apoptotic signaling mediating ATBC-induced microglial toxicity. We retrieved ATBC targets from five prediction databases and AD-related genes from GeneCards and OMIM, obtaining 380 overlapping genes. Five hub genes (SRC, TNF, EGFR, BCL2, and ESR1) were screened via four centrality algorithms. Functional enrichment highlighted neurodegenerative disease pathways and microglia-related apoptotic cascades. We built 127 machine-learning models using two AD GEO cohorts (GSE122603, GSE97760). The robust Lasso + XGBoost ensemble (training AUC = 0.994) identified BCL2, SRC, ESR1, and EGFR as predictive features, with SHAP analysis pinpointing BCL2 as the top contributor. Molecular docking predicted favorable ATBC-BCL2 binding (-5.363 kcal/mol), and 100 ns molecular dynamics simulations supported stable complex formation. In BV2 microglia, ATBC dose-dependently reduced cell viability (IC50 = 59.59 μM), downregulated BCL2 expression, and activated caspase-dependent apoptosis. Collectively, our integrated evidence indicates that BCL2-associated apoptotic signaling mediates ATBC-provoked microglial toxicity, suggesting a plausible mechanistic link between ATBC exposure and AD-related signatures. This study proposes a microglia-oriented mechanistic hypothesis for AD susceptibility and offers a multi-omics paradigm for plasticizer risk assessment.

RevDate: 2026-11-17

Wang L, Jing LP, Chen HC, et al (2026)

TFEB overexpression in excitatory neurons ameliorates amyloid-β pathology via coordinated enhancement of autophagy-lysosome and mitochondrial function.

The Journal of pathology [Epub ahead of print].

The intraneuronal accumulation of amyloid-β (Aβ) is an early pathogenic event in Alzheimer's disease (AD), initiating a pathological cascade that includes synaptic dysfunction, metabolic deficits, and eventual neuronal loss. Transcription factor EB (TFEB), a master regulator of the autophagy-lysosomal pathway (ALP) and mitochondrial homeostasis, represents a promising therapeutic target. However, its efficacy and mechanisms when specifically activated in neurons during the prodromal stage remain unclear. Here, we used an adeno-associated virus (AAV) under the control of the CaMKIIα promoter to achieve excitatory neuron-specific TFEB overexpression in the hippocampal CA1 region of 2 months-old 5×FAD mice. This intervention significantly reduced soluble Aβ levels at 3 months and attenuated amyloid plaque burden, dystrophic neurite formation, and glial activation at 6 months, accompanied by substantial improvements in spatial learning and memory. Mechanistically, transcriptomic and functional analyses revealed that TFEB not only enhanced autophagic flux and lysosomal biogenesis but also promoted the expression of key mitochondrial genes and improved mitochondrial function. In APP695swe-N2a cells, TFEB overexpression increased levels of LC3B-II and LAMP1, enhanced mitochondrial activity and biogenesis (via PGC-1α upregulation), and effectively reduced intracellular Aβ accumulation. Our findings demonstrate that targeted TFEB overexpression in excitatory neurons during early AD pathogenesis initiates a protective cascade by co-activating autophagy-lysosomal clearance and mitochondrial pathways, thereby reducing Aβ accumulation and mitigating downstream pathology. This study highlights the potential of neuron-specific TFEB activation as a cell-type-specific therapeutic approach for early AD intervention. © 2026 The Pathological Society of Great Britain and Ireland.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Luo Y, Chai L, Chen K, et al (2026)

Normative references of corpus callosum across lifespan and application in neurological and neuroimmunological disorders.

Frontiers in neurology, 17:1970514.

BACKGROUND: The corpus callosum (CC) is the largest white matter structure and is often affected in neurological and neuroimmunological disorders. However, previous studies mainly used group-level comparisons. This limits patient-level magnetic resonance imaging (MRI) assessment.

METHODS: In this multicenter retrospective study, 3D T1-weighted MRI data from 24,305 healthy controls aged 4-85 years were used to construct age-,sex-, and estimated total intracranial volume (eTIV)- adjusted normative references for the whole CC and five subregions. Deviation scores were calculated and applied to 4,081 patients with multiple sclerosis (MS, n = 573), neuromyelitis optica spectrum disorder (NMOSD, n = 389), mild cognitive impairment (MCI, n = 308), Alzheimer's disease (AD, n = 623), Parkinson's disease (PD, n = 1,285), and cerebral small vessel disease (CSVD, n = 903). Classification, clinical correlation, and prognostic analyses were performed as exploratory applications.

RESULTS: The volume of CC subregions peaked from early adulthood (central, 26.0 years) to midlife (posterior, 47.2 years; anterior, 47.5 years), forming a "centre-to-periphery" pattern. MS showed negative deviations mainly in central and mid-anterior regions (Cohen's d = -0.28 to -0.30, pFDR<0.001), while CSVD and AD showed widespread negative deviations (d = -0.13 to -0.49). NMOSD, MCI, and PD showed relatively small or regionally limited deviations. Deviation score based classification performance ranged from AUC = 0.598-0.775. Exploratory analyses identified weak correlations between deviation scores and processing speed in MS (Spearman's ρ up to 0.22, p < 0.05) and cognition in CSVD (ρ = 0.12-0.19, p < 0.05) and AD (ρ = 0.10-0.16, p < 0.05). None survived FDR correction. Baseline deviation-based risk groups stratified subsequent relapse and disability outcomes in MS and NMOSD (p < 0.001). An exploratory comparison suggested a nominal difference in baseline CC deviation burden between MCI converters and non-converters to AD.

CONCLUSION: Lifespan normative references of the CC provide a quantitative framework for characterizing individual structural deviations across neurological and neuroimmunological disorders. Exploratory clinical analyses suggest potential applications that require further validation.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Lin XQ, Hua HH, Zhang XY, et al (2026)

Sex-specific alterations in gut microbiome composition in patients with Alzheimer's disease.

Frontiers in microbiology, 17:1915847.

BACKGROUND: The microbiota-gut-brain axis plays a significant role in the pathology of Alzheimer's disease (AD). However, alterations in the gut microbiome structure of AD patients and the sex-specific differences in signature microbial taxa remain inadequately characterized.

METHODS: A total of 100 participants were enrolled, including 60 in the AD case group. Gut microbiota was analyzed by 16S ribosomal RNA (16S rRNA) sequencing. Models incorporating disease group, sex, and a disease-sex interaction term were constructed to test whether sex modifies the effect of AD on gut microbiota α diversity. Stratified analyses were performed to compare α and β diversity between the AD and healthy control (HC) groups in male and female populations, respectively. Differential signature taxa between the two groups were explored using linear discriminant analysis effect size (LEfSe) and random forest analysis.

RESULTS: A total of 36,168 amplicon sequence variants (ASVs) were obtained, with 1,917 ASVs shared between the AD and HC groups. No interaction effect between AD and sex on gut microbiota diversity was observed (interaction p-FDR > 0.05). In the sex-stratified analysis, gut microbiota evenness indices (Simpson, Shannon, and Pielou's indices) were lower in AD patients than in controls among both male and female populations (p-FDR < 0.05), whereas species richness (Chao1 and Observed_species) was significantly reduced only in female AD patients (p-FDR < 0.05). Significant differences in gut microbiota beta diversity were observed between the AD and control groups in both the male population (Stress = 0.213) and the female population (Stress = 0.253) (ANOSIM; males: R = 0.365, p = 0.001; females: R = 0.133, p = 0.001). In the male population, 11 signature taxa, including Bacilli, Lactobacillales, and Macellibacteroides, were significantly enriched in the AD group; in the female population, 12 signature taxa, including [Ruminococcus], Alistipes, and Rikenellaceae, were significantly enriched in the AD group. In the overall prediction of the random forest model distinguishing the AD group from the control group, the accuracy was 85.71% and 90.77% in the male and female populations, respectively, and the taxa contributing most to group classification were Pseudoramibacter_Eubacterium and Lachnospira, respectively (Gini importance = 0.059 for both).

CONCLUSION: The gut microbiota of AD patients exhibits distinct, sex-specific signature taxa.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Wu Y, Xie X, Lyu W, et al (2026)

Gut microbial metabolites: linking gut-immune-brain crosstalk to mental and neuropsychiatric health.

Frontiers in immunology, 17:1993237.

This narrative review adopts the gut-immune-brain axis as the core framework. Literature published 2010-2025 was retrieved from PubMed, Web of Science and ScienceDirect; landmark pre-2010 studies from top journals were also included. Literature was analyzed across five dimensions: metabolite synthesis-transport, intestinal immune regulation, central mediation, disease-pathology links and clinical translation. We elucidate how short-chain fatty acids, tryptophan metabolites and bile acids act as immune messengers to modulate neural homeostasis. Under physiological conditions, they maintain barrier integrity and central immune balance; when dysregulated, they trigger immune disturbance, blood-brain barrier damage and neuroinflammation, promoting Alzheimer's disease, Parkinson's disease, major depressive disorder and chronic insomnia. Moving beyond conventional gut-brain-axis reviews focused merely on gut-brain communication, this work highlights immunity as the critical intermediate node and constructs the cascade "gut microbial metabolites-immune regulation-neural homeostasis-disease". We further summarize biomarker prospects and intervention strategies including dietary fiber, pre-/probiotics and fecal microbiota transplantation. Notably, an ICH-M10-aligned five-stage biomarker validation framework and a gut-brain-immune tri-culture microfluidic model are proposed, offering new directions for mechanistic research and precision therapy for neurological disorders.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Torvell M, Tierney AL, Castillo Morales A, et al (2026)

Regional and progressive protein abundance changes in the App[NLGF] mouse model do not reflect changes in human Alzheimer's disease.

Brain communications, 8(6):fcag427.

There remains a lack of effective disease-modifying treatments for human Alzheimer's disease. Early intervention is key, so there is a need to discover targets present in early disease stages. Obtaining human tissue from patients with early disease is difficult, so mouse models are commonly used to explore (relatively) early events in Alzheimer's disease development, such as the response to amyloid deposition. Here, we investigated early changes in protein abundance in the widely used App[NLGF] Alzheimer's disease model using liquid chromatography-mass spectrometry. Tissue was collected from the hippocampus and cortex of six App[NLGF] and six wild-type (WT) mice at 3 and 6 months to assess regional differences and the impact of aging. Whereas age-related comparisons within the same mouse genotype (3-month versus 6-month) revealed relatively few protein changes, comparisons between App[NLGF] and WT mice demonstrated extensive alterations, with the cortex being more affected than the hippocampus (763 changes versus control in the cortex at 6 months versus 304 in the hippocampus). While many of the changes at 6 months were also present at 3 months, distinct pathways were affected across the two regions. We compared these data to a previous analysis of human post-mortem Alzheimer's disease brain, matched for the regions studied. Comparison of the disease-associated pathways in these data displayed significant divergence between human Alzheimer's disease and the mouse model. This comparison suggests that there are both regional differences in protein abundance in the mouse brain and substantial differences in the mouse response to amyloid deposition compared to that in human Alzheimer's disease. Models should be well characterized and selected with care.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Mandalamari MT, Kumar P, PSR Dwivedi (2026)

Unravelling the anti-Alzheimer potential of Annona muricata fruit through network pharmacology, molecular docking, DFT, molecular dynamics simulations, and MM/PBSA analysis.

Frontiers in bioinformatics, 6:1965394.

BACKGROUND: Alzheimer's disease is characterized by progressive neuronal degeneration that culminates in cognitive impairment. Botanicals represent attractive therapeutic candidates owing to their wide margin of safety and their capacity to act through multiple mechanisms.

MATERIALS AND METHODS: We deployed an integrated computational framework, combining ADME filtering, target-network mapping, binding-affinity prediction, molecular dynamics simulations, binding free-energy calculations, and quantum-chemical analysis to investigate the potential anti-Alzheimer relevance of Annona muricata fruit constituents.

RESULTS: Network pharmacology identified 56 targets shared between 37 screened compounds and Alzheimer's disease, among which APP, TNF, IL6, and AKT1 emerged as the principal hub genes. Among the AD-associated targets, α-synyclein (SNCA) was prioritized for detailed structural analysis based on its docking interactions with the screened constituents. Molecular docking identified T9, T17, and T19 as the constituents showing the most favourable predicted interactions with SNCA, with binding energies of -7.20, -7.001, and -7.25 kcal/mol, respectively. MD simulations indicated stable predicted protein-ligand interactions over the simulated trajectories, while MM/PBSA calculations yielded binding free energies of -12.63 ± 0.37, -12.57 ± 0.01, and -7.89 ± 0.27 kcal/mol for T9, T17, and T19, respectively. density functional theory analysis provided additional information about the chemical reactivity of these 3 compounds.

DISCUSSION: The integrated computational results suggest that selected A. muricata constituents interact with molecular targets and pathways implicated in neuroinflammation and apoptosis pathways in Alzheimer's disease. The structural stability and favourable electronic properties of T9 and T17 highlight their potential as lead scaffolds against SNCA-associated neurodegeneration.

CONCLUSION: Collectively, these computational insights nominate the phytoconstituents T9 and T17 as promising lead candidates for Alzheimer's disease intervention, although prospective cell-based and animal studies remain necessary to confirm their bioactivity.

RevDate: 2026-11-17

Balaji V, Song TA, Yang F, et al (2026)

An interpretable physics-informed graph neural network for forecasting longitudinal tau progression in Alzheimer's disease.

Machine learning. Health, 2(2):025025.

Forecasting the progression of tau pathology by modeling its spatiotemporal dynamics is critical for characterizing Alzheimer's disease (AD), where tau is a key driver of disease progression. Tau is an important prognostic biomarker for AD and is a primary endpoint for many ongoing clinical therapeutic trials. Tau burden can be quantified in vivo using positron emission tomography (PET), while its propagation is hypothesized to follow the structural connectome derived from diffusion tensor imaging (DTI), providing a framework for modeling network-driven tau spread. Deep learning approaches, particularly graph neural networks (GNNs), enable data-driven learning of regional changes in tau burden by leveraging brain connectivity. However, purely data-driven models are prone to overfitting and may fail to capture biologically meaningful propagation patterns. To address this, we present here a physics-informed GNN framework for tau forecasting that incorporates prior models of tau propagation, specifically the Fisher-Kolmogorov-Petrovsky-Piskunov (FKPP) equation and the epidemic spreading model (ESM), as regularization terms in the latent space of the network. Our analysis relies on PET and DTI data from N = 462 amyloid-positive human subjects from the Alzheimer's Disease Neuroimaging Initiative. Our results demonstrate that physics-informed models improve model performance over the unregularized baseline across multiple evaluation metrics, with regularization in the latent space improving robustness compared to that in the feature space. The FKPP formulation achieves the best mean predictive performance, followed closely by ESM. We further implement post-hoc interpretability using Integrated Gradients to identify key regions and connections driving the model's predictions. The interpretability analysis is consistent with the observed performance gains, indicating that physics-based regularization yields more localized attribution within biologically relevant regions. Overall, our findings demonstrate that integrating prior formulations of tau propagation with GNNs enhances predictive accuracy and interpretability, providing a promising framework for modeling network-driven spread of tau pathology.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Chen Y, Rajji TK, Zhukovsky P, et al (2027)

Impact of Cognitive Remediation Combined With Transcranial Direct Current Stimulation on Gray Matter Macrostructure and Microstructure in Older Adults at Risk for Alzheimer's Dementia.

Biological psychiatry global open science, 7(1):100834.

BACKGROUND: Older adults with remitted major depressive disorder or mild cognitive impairment (MCI) are at an increased risk for Alzheimer's dementia (AD). Cognitive remediation (CR) plus transcranial direct current stimulation (tDCS) slows cognitive decline in this population; however, its effects on gray matter macro- and microstructure have not been characterized. We investigated whether CR+tDCS alters cortical structure and whether baseline factors such as brain structure moderate potential changes.

METHODS: Participants from the PACt-MD (Prevention of Alzheimer's Dementia with CR plus tDCS in Mild Cognitive Impairment and Depression) trial received active or sham CR+sham tDCS for 8 weeks and were followed for 2 to 7 years. Gray matter macrostructure (cortical thickness and surface area) was measured via T1-weighted magnetic resonance imaging at baseline, after acute treatment (N = 181), and at study completion (n = 102). Microstructure was assessed using neurite orientation dispersion and density imaging (NODDI). Mixed-effects models examined treatment effects and moderation by baseline factors across brain regions.

RESULTS: No effects of CR+tDCS were observed on gray matter macro- or microstructure. Baseline cortical thickness moderated temporal lobe thickness changes, strongest in the entorhinal cortex over follow-up (p FDR = .010). Baseline NODDI measures moderated microstructural changes, strongest in the rostral middle frontal orientation dispersion index after acute treatment (p FDR < .001). There were no moderation effects of diagnosis or APOE status.

CONCLUSIONS: CR+tDCS does not produce uniform structural changes but interacts with baseline macro- and microstructure to shape longitudinal trajectories. Findings support the potential for precision approaches in preventive interventions for older adults at risk for AD.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Handschuh S, Reindl S, Binder F, et al (2026)

Accelerated Hit Identification and Optimization of a Novel Class of Cellularly Active QPCT/L Inhibitors.

ACS medicinal chemistry letters, 17(11):2274-2282.

QPCT and its Golgi-bound analogue QPCTL catalyze the conversion of N-terminal glutamines into pyroglutamates, a modification that influences diverse biological processes, including Aβ oligomerization, chemokine stabilization, and CD47-SIRPα signaling. Consequently, QPCT/L inhibitors have therapeutic potential in Alzheimer's disease, cancer, and fibrosis. Here, we describe the identification of QPCT/L inhibitors using a virtual screening strategy in which less than 0.1% of our in-house compound library was selected based on similarity to the bioactive conformations of known QPCT/L inhibitors. This approach yielded previously unknown QPCT/L inhibitor chemotypes and substantially accelerated hit discovery. Structure-guided optimization of one quinazolidinone series afforded a potent cellular tool compound BI-3614 with improved activity over previously reported inhibitors, which is available free of charge on opnMe.com. The campaign provided valuable insights, revealing the critical impact of water networks on binding-mode prediction and the profound influence of subtle electronic changes on π-stacking interactions, emphasizing the importance of experimental validation of computational design hypotheses.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Shu Y, F Yang (2026)

Mortality trends and disparities in older U.S. adults with coexisting chronic obstructive pulmonary disease and Alzheimer's disease, 1999-2023.

Pakistan journal of medical sciences, 42(10):2621-2628.

OBJECTIVES: Chronic obstructive pulmonary disease (COPD) and Alzheimer's disease (AD) are leading causes of death among older adults. Their coexistence complicates clinical management and increases disease burden; however, long-term national mortality trends for this comorbidity remain poorly characterized.

METHODOLOGY: We conducted a retrospective analysis at the Department of Respiratory and Critical Care Medicine, Beijing Bo'ai Hospital, China Rehabilitation Research Center, Capital Medical University, using U.S. mortality data from the CDC WONDER Multiple Cause of Death database (1999-2023) for individuals aged ≥65 years with both COPD (ICD-10: J40-J44) and AD (ICD-10: G30) listed as causes of death. Age-adjusted mortality rates (AAMRs) and annual percent change (APC) were calculated across age, sex, race/ethnicity, census region, and urbanization level.

RESULTS: From 1999 to 2023, 151,250 deaths were recorded with COPD-AD comorbidity. Age-adjusted mortality rates increased significantly among adults ≥85 years (AAMR: 46.46 to 59.31 per 100,000; average annual percent change [AAPC] = 1.01%). Sex-specific trends diverged: AAMR declined in males (AAPC = -1.06%) but rose in females (AAPC = 1.31%). Geographically, the Northeast experienced a significant decline (AAPC = -1.61%), whereas both metropolitan (AAPC = 1.29%) and nonmetropolitan areas (AAPC = 2.02%) showed increases, with a steeper rise in nonmetropolitan regions.

CONCLUSION: Mortality trends for COPD-AD comorbidity among older U.S. adults exhibited substantial demographic and geographic disparities over the 25-year period. These findings underscore the need for targeted public health strategies and further etiologic investigation.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Sabnis RW, AR Sabnis (2026)

Novel Compounds as TREM2 Agonists for Treating Parkinson's Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Nasu-Hakola Disease, and Stroke.

ACS medicinal chemistry letters, 17(11):2311-2312.

Provided herein are novel compounds as TREM2 agonists, pharmaceutical compositions, use of such compounds in treating Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, frontotemporal dementia, Nasu-Hakola disease and stroke, and processes for preparing such compounds.

RevDate: 2026-11-17

Yoon S, Patterson M, Sun F, et al (2026)

Attitudes Towards Risks and Benefits of Using Generative Artificial Intelligence (GenAI) for African American Family Members of a Person with Dementia.

Humanities & social sciences communications [Epub ahead of print].

Adopting generative AI (GenAI) technologies in health care is imminent, making it urgent to address systemic barriers to equitable technology. GenAI has the potential to alleviate the burden on healthcare professionals and care coordination by crafting personalized messages for family members of a person with Alzheimer's Disease and Related dementia (ADRD) who are at high risk. We conducted a cross-sectional online survey from April 8 to May 3, 2024, among 527 family members of a person with ADRD or memory issues, recruited via social media and flyer postings at an urban medical center. We applied machine learning techniques to characterize demographic and caregiving factors that predict attitudes toward the risks and benefits of using GenAI for caregiving. We examined these factors across three representative scenarios at the individual level of the socioecological model. Notably, Black or African American participants were more than twice as likely as White participants to express an overall positive view of the AI tools (OR 2.23, 95% CI 1.43-3.48; p<0.001). While the benefits of using GenAI for family members were recognized well among all age groups, those aged 25-34 expressed more caution. Engaging these younger family members as community partners is critical to identifying anticipated risks and to ensuring that GenAI implementation promotes health equity rather than reinforcing existing disparities for high-risk populations.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Markus HS (2026)

Vascular risk in dementia; underappreciated but tractable.

Cerebral circulation - cognition and behavior, 11:100572.

Vascular contributions to dementia are substantial but remain under-recognised, and vastly underfunded relative to Alzheimer's disease. This commentary discusses the recently published World Stroke Organisation Scientific statement on the vascular contribution to dementia, in which a multidisciplinary panel of global experts review the different ways in which vascular risk contributes to dementia, and highlights opportunities for prevention and treatment. Vascular cognitive impairment encompasses both post-stroke cognitive impairment and chronic cerebral small vessel disease which is the commonest vascular pathology underlying dementia. Cerebrovascular disease, particularly cerebral small vessel disease also interacts with Alzheimer's disease pathology to increase the chance that Alzheimer's disease pathology will result in clinical dementia. Evidence from randomised controlled trials demonstrates that intensive blood pressure control can reduce all-cause dementia, supporting vascular risk modification as a feasible preventive strategy to reduce not only vascular dementia, but also all cause dementia. Recent insights into the pathogenesis of cerebral small vessel disease are generating new potential therapeutic targets. These include impaired cerebral autoregulation, endothelial dysfunction, extracellular matrix disruption and blood brain barrier permeability, glymphatic dysfunction, and neuroinflammation. Ongoing trials are evaluating vasodilators, PDE5 inhibitors, neuroprotective agents, GLP-1 agonists, and remote ischaemic conditioning. Greater research investment is required to translate these mechanistic advances into effective future therapies. Despite its importance vascular dementia is markedly underfunded compared with Alzheimer's disease. For example, in the United States in 2025 the National Institute of Health (NIH) spent $3.62 billion on Alzheimer's disease research, compared with $0.49 billion on vascular dementia. Similar inequalities are seen in many other counties worldwide, despite the fact that cerebrovascular disease accounts for about 30% of all dementia [4]. A concerted effort from governments, academic institutions, researchers, and particularly funders, worldwide is required to increase research, and develop new treatments, for this important condition.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Yang S, Jing Q, Duan W, et al (2026)

Microglial function alterations during healthy ageing and canine cognitive dysfunction revealed by single-nucleus and spatial transcriptomics.

National science review, 13(20):nwaf388.

Canines, which spontaneously develop Alzheimer's disease (AD)-like pathology with age, serve as valuable translational models for studying AD. However, the cellular molecular functions of the canine brain in healthy ageing and/or canine cognitive dysfunction (CCD) have not yet been studied. Here, we present a multiregional healthy canine brain ageing atlas using single-nucleus (sn)RNA-seq, alongside a CCD versus non-CCD brain atlas generated using both snRNA-seq and Stereo-seq. Cellular heterogeneity analysis during healthy brain ageing revealed that glial cells undergo the most pronounced alterations, with previously uncharacterized ageing-related subtypes identified in microglia and astrocytes that contribute to myelin synthesis. This analysis also identified and validated ZEB1 as a previously unrecognized transcription factor regulating oligodendrocyte differentiation, with expression progressively declining with age. Pathogenetic analysis of CCD revealed that the interaction between microglial C1QA and CRT in dentate gyrus granule cells is a critical mediator of synaptic loss. Furthermore, compared with microglia from normally ageing canines, the microglia from CCD-canine exhibited a significant decrease in the ability to metabolize amyloid precursor protein. Overall, this study provides a single-nucleus and spatial transcriptomic atlas of the ageing and CCD brain, offering insights into molecular features underlying cognitive dysfunction.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Chumki SR, Palma AM, Ardic F, et al (2026)

Incidence and Clinical Relevance of Somnolence and Sedation with Brexpiprazole in Patients with Agitation Associated with Dementia Due to Alzheimer's Disease: Post Hoc Analysis of Clinical Trials.

Neuropsychiatric disease and treatment, 22:650271.

INTRODUCTION: Agitation is a common and challenging aspect of Alzheimer's dementia. Many psychotropic medications (used off-label to treat agitation) are associated with somnolence and sedation, which can impact adherence, functioning, falls, and cognition. This post hoc analysis aimed to analyze the incidence and clinical relevance of somnolence, sedation, and hypersomnia with brexpiprazole.

METHODS: The analysis used pooled data from two Phase 3, 12-week, randomized, double-blind, placebo-controlled, fixed-dose trials in participants with Alzheimer's dementia and agitation (ClinicalTrials.gov identifiers: NCT01862640, NCT03548584); and a 12-week, active-treatment, single-arm, extension trial (NCT03594123). The trials were conducted in Europe, Russia, and the US between 2013 and 2022. The incidence, dose-related patterns, severity, impact on discontinuation, and timing of somnolence, sedation, and hypersomnia as treatment-emergent adverse events were calculated descriptively over 12 and 24 weeks.

RESULTS: Over 12 weeks, the incidence of combined somnolence/sedation was 3.0% on brexpiprazole 1-3 mg (somnolence, 2.8%; sedation, 0.2%; N=503) compared with 0.8% on placebo (N=251); number needed to harm (95% confidence interval), 46 (25-298). The incidence of hypersomnia was zero. The incidence of somnolence/sedation had an apparent dose-related pattern, peaking at 3.9% (3 mg). Somnolence and sedation were mostly mild in severity, and led to discontinuation in one participant on brexpiprazole. The median (interquartile range) time to somnolence or sedation was 24 (5-45) days with brexpiprazole and 37 (21-53) days with placebo. Among participants who took brexpiprazole for 24 weeks (N=163), the incidence of somnolence was 4.9% (zero for sedation and hypersomnia), which led to discontinuation in one participant.

CONCLUSION: This post hoc analysis supports the tolerability of brexpiprazole with respect to somnolence and sedation in a sample of older adults receiving treatment for agitation in Alzheimer's dementia.

RevDate: 2026-11-17

Yilmazer-Hanke D, Alexiou P, Tuzzi E, et al (2026)

3D pattern of cerebral amyloid angiopathy (CAA) from leptomeninges to vascular layers of the human cerebral cortex in comparison to age- and amyloid-beta (Aβ) burden-related capillary CAA.

Brain pathology (Zurich, Switzerland) pii:e70166 [Epub ahead of print].

In cerebral amyloid angiopathy (CAA), the relationship of perivascular β-amyloid (Aβ) deposits to Aβ in vessel walls and AD-related pathology is not fully understood. Here, we performed 3D analyses of vascular and perivascular circumferential/dyshoric Aβ deposits with Aβ17-24- and Aβ1-40-labeling antibodies using single-/double-/multi-label immunostaining in thick brain sections, and in tissue sequentially cleared with DEEP-Clear and CUBIC-L in human CAA. Arterial and capillary walls showed both Aβ1-40 and Aβ17-24 labeling, extending over several branching points, with vessel segments containing Aβ1-40 considerably dilated. Ten distinct 3D arterial/arteriolar and capillary CAA categories were identified and quantified with Aβ17-24 in the leptomeninges, and vascular layers (superficial, middle, deep, and juxtacortical) of nine cerebral cortical areas. While four categories reflected Aβ in arterial walls (tunica media and adventitia) and the perivascular brain parenchyma (fleecy or fibrillary), in six capillary CAA categories three showed gaps between dyshoric Aβ deposits and Aβ in capillary walls, and three were gapless (dyshoric Aβ deposits attached to capillary walls). Factor analysis extracted the factors "arterial CAA," "Aβ load-related capillary CAA" with gaps, and gapless "age-related capillary CAA," with factor 1 associated with the APOE ε4 genotype, factor 2 with cortical Aβ burden, and factor 3 with age. Leptomeningeal/superficial cortical vascular layers were more severely affected in "arterial CAA," while the two capillary CAA types were prominent in middle/deep cortical layers. Layer and age distribution of Aβ1-40 was similar to Aβ17-24 in all three CAA types. Thus, our 3D CAA analyses using thick brain sections and light sheet microscopy distinguished arterial CAA from two different capillary CAA types. Opposite layer patterns of arterial and capillary CAA and the distinction of two capillary CAA forms based on their relationship either to Aβ load/APOE ε4 genotype or age suggests differences in CAA pathogenesis and mechanisms in pericapillary Aβ drainage.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Liang L, Zhang J, Y Zhang (2026)

TUBB2A as a Candidate Therapeutic Target for Alzheimer's Disease: Orotidine-Mediated Metabolic Mechanisms and Druggability.

ASN neuro, 18(1):2754640.

As the most prevalent neurodegenerative disorder, Alzheimer's disease (AD) poses a pressing need for novel therapeutic targets. This study was designed to address this gap by screening and validating druggable genetic targets nominally associated with AD through an integrative multi-omics approach. Mendelian randomization (MR) screened the druggable genome. GTEx eQTL data and differential expression analysis identified core candidates. SMR, GSMR, and cross-tissue eQTL validation assessed putative causal effects and cross-tissue generalizability. Single-cell RNA sequencing (scRNA-seq) dissected cell type-specific expression. Virtual knockout combined with cell-cell communication analysis elucidated regulatory mechanisms. Mediation analysis evaluated Cerebrospinal fluid (CSF) metabolite involvement, and molecular docking screened therapeutic agents. Genetically predicted TUBB2A expression was nominally associated with AD risk. Virtual knockout analysis revealed that TUBB2A deficiency induced significant upregulation of SLC1A3 and HIF3A, suggesting compensatory glutamate clearance and hypoxic stress responses. Nominal mediation analysis suggested that the CSF metabolite orotidine may be involved in the TUBB2A-AD association. Molecular docking revealed high binding affinity between Eribulin mesylate and TUBB2A. This study identifies TUBB2A as a priority candidate gene for further validation in AD, proposes a potential role for orotidine in TUBB2A-related AD susceptibility, and identifies eribulin mesylate as a potential therapeutic agent worthy of further investigation, thereby generating testable hypotheses for future mechanistic and therapeutic studies. susceptibility, and identifies eribulin mesylate as a potential therapeutic agent worthy of further investigation, thereby generating testable hypotheses for future mechanistic and therapeutic studies.

RevDate: 2026-11-17

Anania V, Jeurissen B, Billiet T, et al (2026)

The ORION framework for outlier-robust parameter estimation in diffusion kurtosis imaging.

Scientific reports, 16:37885.

Diffusion-weighted images are susceptible to intensity outliers that degrade the accuracy and precision of diffusion tensor and diffusion kurtosis imaging (DKI) parameter estimates. In this work, we introduce ORION, a voxel-wise framework for outlier-robust DKI parameter estimation based on constrained linear least squares estimators. ORION is designed to detect intensity outliers in both diffusion-weighted and non-diffusion-weighted images, ensuring the robustness of DKI metrics against artifactual signal dropouts and signal overshoots. First, the performance of the proposed framework in terms of outlier detection and statistical parameter estimation is compared to that of the previously proposed iterative reweighted linear least squares (IRLLS) outlier-robust approach in a Monte Carlo simulation framework. Next, we compare the DKI metrics extracted from two synthetic outlier-corrupted datasets using ORION, IRLLS, and a conventional weighted linear least squares (WLLS) approach. The synthetic datasets were realistically generated from in vivo MRI data from two participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI), with one dataset affected by signal dropout and the other by signal overshoot. In comparison to WLLS, both ORION and IRLLS achieved significantly lower errors in estimating white matter DKI metrics in regions affected by intensity outliers, with ORION also outperforming IRLLS on a subset of metrics under signal dropout conditions. Finally, the DKI metrics extracted from the in vivo datasets were found to be in line with the results obtained on the synthetic data. In conclusion, ORION successfully detects and rejects intensity outliers improving upon conventional DKI estimation techniques.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Nepal P, Al Bashit A, Stewart TC, et al (2026)

Scanning X-ray microdiffraction studies of protein accumulation and tissue loss in thin sections of human brain tissue in Alzheimer's disease.

Scientific reports, 16:37946.

Neurodegeneration in Alzheimer's disease is characterized by accumulation of pathological protein deposits including Aβ plaques, tau tangles and diffuse neuropil threads accompanied by wide-spread tissue loss. While dense protein deposits are readily observed by conventional methods, histology struggles to properly capture microscopic evidence of absences corresponding to tissue loss. This study demonstrates the use of scanning X-ray microdiffraction to quantitatively evaluate both protein accumulation and tissue loss in thin sections of human brain tissue across anatomical regions and stages of disease. We show that scanning small-angle microdiffraction can quantify the material properties of tissue through mapping the presence of sub-micron-sized "scattering voids", imaging a tissue attribute that is typically invisible and providing an alternative metric for tissue integrity. Correlation of x-ray data with images of silver-stained sections provided quantitative assessment of protein accumulation readily observed in densely stained features. Regions containing large and abundant scattering voids proved to be highly fragile and closely correspond to locations that were damaged during subsequent tissue processing. This work demonstrates the use of scanning microdiffraction for mapping the abundance of these voids in tissue, providing a detailed description of a phenomena that is typically invisible to histology and utilizing it to study tissue structure across multiple brain regions in diseased human tissue.

RevDate: 2026-11-17

Jain B, Dey S, AB Dey (2026)

Development and regional validation of a literacy-fair verbal cognitive screen for older adults in India.

Journal of Alzheimer's disease : JAD [Epub ahead of print].

BackgroundBrief cognitive screens could narrow India's dementia detection gap, but widely used instruments depend on reading, writing, or clock-drawing and lose accuracy in the large illiterate older population; Alzheimer's disease and related dementias drive most of this burden.ObjectiveTo derive and validate a fully verbal, literacy-fair candidate cognitive screening model.MethodsIn LASI-DAD Wave 1 (n = 4096) we derived a screen from prop-free verbal tasks (LASSO then forward selection) against algorithmic DSM-5 classification, compared discrimination (AUC) with reconstructed Hindi Mental State Examination (HMSE), Mini-Cog, Community Screening Instrument for Dementia (CSID) and Telephone Interview for Cognitive Status (TICS), performed leave-one-region-out validation and addressed incorporation bias using clinician Clinical Dementia Rating (CDR) ratings (n = 2527).ResultsThe sample was 57.5% illiterate; weighted prevalence was 26.7% (any impairment) and 9.0% (dementia). A four-item model-word-list learning, orientation to time, object naming, animal fluency ("Verbal-4")-reached AUC 0.757 for any impairment and 0.785 for dementia, indistinguishable from the HMSE, higher than the Mini-Cog, CSID and TICS (all p < 0.001), and similar across literacy (0.778 versus 0.776). In the non-random CDR-rated subsample, dementia discrimination was 0.872 against the clinician CDR versus 0.775 against the DSM-5 algorithm. Any-impairment discrimination attenuated in South India (0.688), analyses suggesting substantial case-mix and/or reference-standard contributions. A positive screen predicted mortality (adjusted HR 1.63, 95% CI 1.39-1.90).ConclusionsThis candidate screening model matched full-battery accuracy without a literacy gradient, held against a partially independent clinician standard, and carried independent prognostic information; it requires prospective calibration into an operational score before field use.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Lake DT, Unruh MA, Kim D, et al (2026)

Higher Primary Care Reimbursements and the Quality of Care for Dually-Eligible Medicare Beneficiaries With Alzheimer's Disease and Related Dementias in Skilled Nursing Facilities.

Health services research, 61(6):.

OBJECTIVE: To examine whether increased Medicaid primary care reimbursement improved the quality of care for dually eligible beneficiaries (DE) with Alzheimer's disease and related dementias (ADRD) in skilled nursing facilities (SNFs).

STUDY SETTING AND DESIGN: We studied DE beneficiaries with ADRD admitted to US Medicare- and Medicaid-certified SNFs from 2012 to 2019 using a difference-in-differences approach. We exploited the Affordable Care Act's primary care fee bump (2013-2014) as a natural experiment, leveraging two sources of policy variation: the implementation (phase-in, 2012 vs. 2013-2014) and the expiration (phase-out, 2013-2014 vs. 2015-2019). We compared outcomes in states where providers received full reimbursement increases against those with partial or no increases.

A national 20% sample of Medicare fee-for-service beneficiaries linked to Minimum Data Set assessments was used. The sample included DE beneficiaries aged 65 and older with ADRD and one or more SNF stays during the study period. Outcomes included primary care visit volume, seven measures of quality (30-day hospital readmissions, functional improvement, successful community discharge, 4 nursing-sensitive quality measures), SNF length of stay, and total Medicare expenditures.

PRINCIPAL FINDINGS: The fee bump was not associated with significant changes in primary care visit volume, seven quality measures, length of stay, or total Medicare expenditures. Null findings persisted in states with the largest reimbursement increases and were robust to synthetic difference-in-differences specifications and alternative control groups.

CONCLUSIONS: Fee-for-service reimbursement increases targeted at the visit level did not improve outcomes for DE beneficiaries with ADRD in SNFs. Structural barriers, including the disconnect between billing entities and clinicians and regulatory visit mandates that create a volume floor, may have limited the responsiveness of physicians' provision of care to these reimbursement changes and associated quality measures.

RevDate: 2026-11-17

Jia H, Liu J, Lubetkin EI, et al (2026)

Impact of 22 Comorbidities on Number of Hospitalizations and Emergency Department Visits in U.S. Community-Dwelling Older Adults With Alzheimer's Disease and Related Dementias (AD/ADRD).

Journal of applied gerontology : the official journal of the Southern Gerontological Society [Epub ahead of print].

ObjectivesExamine the impact of 22 comorbidities on number of hospitalizations and Emergency Department (ED) visits among community-dwelling persons with Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD).MethodsAnalyzed 2018-2019 Medicare Claims data for 7.1 million beneficiaries aged ≥65 with AD/ADRD. Each comorbidity's impact was assessed using net effect (NE), a measure of attributable risk for multiple interacting factors.ResultsPneumonia showed the highest contribution to all-cause hospitalizations (NE = 1.58), indicating that pneumonia contributed 1.58 all-cause hospitalizations per year. Acute myocardial infarction had an NE of 1.37; hip fracture, 1.20; anemia, 0.89; and stroke, 0.78. Stroke had the highest contribution to all-cause ED visits (NE = 0.477), followed by arthritis (0.421), pneumonia (0.400), depression (0.394), hypertension (0.325), and hip fracture (0.323).ConclusionOur results highlight a large discrepancy in how the various comorbidities of AD/ADRD impact healthcare utilizations. Certain conditions, particularly pneumonia and arthritis, may be key targets for reducing hospitalizations and ED visits.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Das R, Biswas S, D Mukhopadhyay (2026)

Amyloid-β42 Drives Collagen-Independent Activation of Discoidin Domain Receptor 2 in Alzheimer's Disease.

Biochemistry, 65(22):3681-3692.

Discoidin domain receptor 2 (DDR2), a receptor tyrosine kinase (RTK) family member, plays a pivotal role in collagen-mediated signaling, influencing several key cellular processes. In Alzheimer's disease (AD), DDR2 expression and activity are significantly upregulated. While collagens, the endogenous ligands of DDR2, either remain unchanged or are downregulated in AD-like conditions, Amyloid-beta 42 (Aβ42) has been found to activate DDR2 noncanonically in the absence of collagen. Additionally, DDR2 naturally translocates to the nucleus in the neuroblastoma cell line SH-SY5Y, and the nuclear pool of DDR2 further increases in the presence of Aβ42, suggesting a novel pathological role for DDR2 in AD. The E113K mutant of DDR2, where the collagen-binding site has been compromised, fails to get activated by collagen, whereas Aβ42 could still activate it. Furthermore, the DDR2 inhibitor WRG-28 effectively inhibits Aβ42 induced phosphorylation of the protein. We have modeled the ectodomain of DDR2 in silico, extending it through the transmembrane helix and subsequently docked the Aβ42 pentamer to provide a structural hypothesis for elucidating the mechanistic basis of Aβ-mediated kinase activation. Additionally, we analyzed WRG-28 binding by forming a ternary complex among DDR2, Aβ42, and WRG-28. Our structural analyses offer key insights into the molecular mechanisms governing DDR2 activation by Aβ42 and its inhibition by WRG-28 in the AD cell model, providing a foundation for targeted therapeutic strategies.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Shi K, Zhang C, Chen Y, et al (2026)

Structure-Engineered Lipid-Mineral Nanoparticles for Ligand-Free Myeloid RNAi Delivery in Alzheimer's Disease.

ACS nano, 20(45):30742-30762.

Peripheral myeloid cells are key regulators of systemic inflammation and promising targets for immune intervention in Alzheimer's disease (AD). However, selective in vivo small interfering RNA (siRNA) delivery to these cells remains challenging because conventional lipid nanoparticles often exhibit predominant hepatic accumulation and usually require ligand or antibody modification for immune-cell targeting. Here, we report a structure-engineered lipid-mineral nanoparticle platform, termed MCP, for ligand-free myeloid RNA interference (RNAi) delivery. MCP integrates a calcium phosphate mineral phase with a phosphatidic acid-enriched lipid interface, enabling efficient siRNA incorporation. The Ca2+-lipid cooperative architecture promoted macropinocytosis-dependent uptake and preferential siRNA delivery to peripheral myeloid cells in vivo, particularly Ly6Chigh monocytes and macrophages, with enhanced delivery under AD-associated inflammatory conditions. Systemic delivery of MCP carrying siRNA against triggering receptor expressed on myeloid cells 1 (TREM1) attenuated neuroinflammatory and neurodegenerative pathology in an AD mouse model, supporting peripheral myeloid reprogramming as a route to modulate central nervous system (CNS) disease progression. Notably, MCP also achieved efficient TREM1 silencing in AD patient-derived peripheral blood mononuclear cells (PBMCs) and restored TREM1 expression toward healthy-control levels. This work establishes a structure-driven, ligand-free lipid-mineral RNAi platform for peripheral immune intervention in AD.

RevDate: 2026-11-17

Yu R, Wang T, Sun S, et al (2026)

Global, regional, and national burden of Alzheimer's disease and other dementias with a focus on populations aged 40 years and older, 1990-2023, and projections to 2040: a systematic analysis based on the Global Burden of Disease Study 2023.

Neuroepidemiology pii:9080744 [Epub ahead of print].

Objective To comprehensively assess long-term epidemiological trends in Alzheimer's disease and other dementias (ADOD) from 1990 to 2023 using data from the Global Burden of Disease Study 2023 (GBD 2023), and to project future burden to 2040 globally and in China. Methods We analysed age-standardised prevalence, incidence, mortality, and disability-adjusted life years (DALYs) across 204 countries and territories. Temporal trends were assessed using Joinpoint regression. Decomposition analysis quantified the contributions of population growth, population ageing, and epidemiological change to burden increases. Socioeconomic inequality was evaluated using concentration indices. Bayesian age-period-cohort models were applied to project age-specific burden through 2040. Results From 1990 to 2023, global age-standardised rates of ADOD remained broadly stable, whereas absolute numbers increased substantially, driven primarily by population ageing and population growth. Women consistently experienced higher burden than men across all metrics. Burden levels were highest in high sociodemographic index (SDI) settings, while the fastest growth occurred in middle and low SDI regions. Risk attribution analyses identified high fasting plasma glucose as the leading modifiable contributor to ADOD burden globally. Projections indicated that future increases will be highly concentrated among adults aged 70 years and older. In China, age-standardised prevalence and incidence among adults aged ≥40 years are projected to rise more steeply than the global average, particularly in older age groups. Conclusion Although age-standardised rates of ADOD are stabilising globally, population ageing will continue to drive a rapidly growing absolute burden over the next two decades. The concentration of future burden in older adults and in rapidly ageing middle-income countries underscores the need for age-targeted prevention strategies, early metabolic risk control, and health-system planning that explicitly accounts for age structure and socioeconomic inequality.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Michoń J, Pujanek P, Hryniewicz WW, et al (2026)

Dietary and endogenous fructose metabolism in Alzheimer's disease: a critical review of mechanistic, preclinical, and epidemiological evidence.

Metabolic brain disease, 41(1):.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia worldwide. It is characterized by the accumulation of β-amyloid plaques, the formation of neurofibrillary tangles (NFT's), synaptic loss, and brain atrophy. Although age and genetic factors, such as the presence of the APOE ε4 allele, remain the main risk factors, increasing attention is being paid to modifiable metabolic factors. Excessive fructose intake may contribute to neurodegeneration through mechanisms involving insulin resistance, oxidative stress, inflammation, mitochondrial dysfunction, and activation of the so-called "fructose survival pathway". These processes may disrupt brain energy metabolism and increase β-amyloid accumulation, particularly in the hippocampus. Studies suggest that high sugar consumption, especially in the form of sugar-sweetened beverages, may be associated with an increased risk of Alzheimer's disease. Although the available data are still limited, excessive fructose intake may be associated with the development of Alzheimer's disease. Further research is needed to more precisely determine its role and the effectiveness of dietary interventions in the prevention of Alzheimer's disease.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Joshi D, Uniyal S, Singh SK, et al (2026)

Targeting Energy Metabolism and Tryptophan Pathways in Alzheimer's Disease for Developing Therapeutic Strategies.

Molecular neurobiology, 63(1):.

Alzheimer's disease (AD) is the primary cause of dementia worldwide and carries a high socioeconomic burden. However, despite the fact that such pathological features as amyloid-beta plaques and neurofibrillary tangles are considered hallmark traits of AD, therapeutic approaches targeting these pathological features have shown limited clinical efficacy to date. Recent scientific discoveries have drawn attention to the importance of metabolic processes preceding neurodegeneration. Reduced glucose utilization and impaired oxidative phosphorylation (OXPHOS) are associated with bioenergetic deficits that may increase neuronal vulnerability to damage. In addition, neuroinflammation is associated with altered tryptophan metabolism through the kynurenine pathway and may favor the production of potentially neurotoxic metabolites. Despite these separate aspects of AD, the interaction between impaired bioenergetics and altered tryptophan metabolism in the brain has not been sufficiently studied. This gap complicates the development of multi-targeted treatment strategies. The purpose of this narrative review is to examine how gut dysbiosis, immune activation, mitochondrial oxidative phosphorylation (OXPHOS) impairment, redox imbalance, and tryptophan-kynurenine pathway dysregulation interact and may contribute to AD development and progression, including associated neuropsychiatric symptoms. We examine whether NAD[+] depletion and rerouting of tryptophan metabolism may act as key nodes linking mitochondrial respiratory failure with the generation of neurotoxic kynurenine metabolites, excitotoxic glutamatergic signaling, loss of neurotrophic support, and synaptic dysfunction, and to analyze existing and emerging therapeutic strategies that target these interconnected pathways. In addition, this review highlights potentially promising interventions, such as NAD[+] precursor supplementation, central nervous system insulin delivery, and modification of gut microbiome. Here we propose that the energy-tryptophan metabolic axis is a promising but underexplored area of AD research. Targeting these convergent bioenergetic and metabolomic pathways may support precision intervention strategies that could extend beyond conventional amyloid-centric paradigms to address broader neurodegenerative and neuropsychiatric syndromes.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Wang J, Cong P, Feng E, et al (2026)

Intranasal delivery of a ROS-activatable myeloperoxidase inhibitor alleviates Alzheimer's-like symptoms and pathology.

Proceedings of the National Academy of Sciences of the United States of America, 123(47):e2603280123.

Chronic neuroinflammation and oxidative stress are important contributors to Alzheimer's disease (AD). Myeloperoxidase (MPO), a key driver of oxidative inflammation released mainly by activated microglia in the neurodegenerative brain, is a potential therapeutic target to inhibit the neuroinflammatory cascade and oxidative damage in AD, but the underlying mechanisms remain unexplored, and achieving targeted brain delivery of an MPO inhibitor and minimizing systemic effects remain significant challenges. We addressed these limitations by first establishing that genetic deletion of MPO in the 5XFAD mouse model improved memory performance and reduced amyloid deposition, validating MPO as a therapeutic target. We then developed a liposome-encapsulated reactive oxygen species (ROS)-activatable MPO inhibitor (LERAMI). LERAMI uniquely combines targeted delivery with on-demand drug release, utilizing a ROS-sensitive linker to selectively release MPO inhibitors in ROS-rich regions within the AD microenvironment, minimizing off-target effects and systemic toxicity. In the 5XFAD mouse model. By reducing MPO expression and activity, LERAMI significantly improved cognitive performance, accompanied by decreased microglial activation, attenuated oxidative DNA damage, improved synaptic and neuronal density, and reduced amyloid burden. RNA sequencing revealed a robust hippocampal transcriptomic reprogramming, with upregulation of pathways critical for synaptic plasticity, calcium signaling, axon guidance, and neuroprotection, along with downregulation of inflammatory and immune response pathways. These findings demonstrate that targeted ROS-activatable MPO inhibition with LERAMI represents a promising therapeutic strategy for AD and potentially other neuroinflammatory diseases, offering a unique approach to mitigate neuroinflammation, preserve synaptic integrity, and restore cognitive function.

RevDate: 2026-11-17

Raja WK, Mungenast AE, Lin YT, et al (2026)

Correction: Self-organizing 3D human neural tissue derived from induced pluripotent stem cells recapitulate Alzheimer's disease phenotypes.

PloS one, 21(11):e0362833 pii:PONE-D-26-55097.

[This corrects the article DOI: 10.1371/journal.pone.0161969.].

RevDate: 2026-11-17
CmpDate: 2026-11-17

Atalar A, Adar N, S Okyay (2026)

"Pipe-Laying": A novel fusion of 3D MRI and health records for the early detection and diagnosis of Alzheimer's disease using deep learning.

PloS one, 21(11):e0362862 pii:PONE-D-24-36193.

Alzheimer's disease (AD) is a prevalent form of dementia that impacts brain cells. Although its likelihood increases with age, there is no transitional period between its stages. In order to enhance diagnostic precision, physicians rely on clinical judgments derived from interpreting health data, considering demographics, clinical history, and laboratory results to detect AD at an early stage. While patient cognitive tests and demographic information are primarily presented in text, brain scan images are presented in graphic formats. Researchers typically use different classifiers for each data format and then merge the classifier outcomes to maximize classification accuracy and utilize all patient-related data for the final decision. However, this approach leads to low performance, diminishing predictive abilities and model effectiveness. We propose an innovative approach that combines diverse textual health records (HR) with three-dimensional structural magnetic resonance imaging (3D sMRI) to achieve a similar objective in computer-aided diagnosis, utilizing a novel deep learning technique. Health records, encompassing demographic features like age, gender, apolipoprotein gene, and mini-mental state examination score, are fused with 3D sMRI, enabling a graphic-based deep learning strategy for early AD detection. The fusion of data is accomplished by representing textual information as graphic pipes and integrating them into 3D sMRI, a method referred to as the "pipe-laying" method. This unified approach enables simultaneous processing of textual health records and 3D sMRI data within a single convolutional framework. Experimental results from over 4000 sMRI scans of 780 patients in the AD Neuroimaging Initiative (ADNI) dataset demonstrate that the pipe-laying method enhances recognition accuracy rates for Early Mild Cognitive Impairment (EMCI) and Late Mild Cognitive Impairment (LMCI) patients, accurately classifying all AD patients. In a 4-class AD diagnosis scenario, encompassing AD, LMCI, EMCI, Cognitively Normal (CN) accuracy improved from 86.87% when only 3D images were used to 90.00% when 3D sMRI and patient health records were included. Thus, the positive impact of combining 3D sMRI with HR on 4-class AD diagnosis was established.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Mukesha D, Firat H, Sacco G, et al (2026)

Integrating large-scale serum baseline metabolomics and APOE ε4 genotype status for the non-invasive detection of Alzheimer's disease in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.

PloS one, 21(11):e0356137 pii:PONE-D-26-03668.

INTRODUCTION: Accurate Alzheimer's disease (AD) detection remains challenging and often requires invasive or costly procedures. Blood-based metabolomic signatures offer a promising non-invasive comparative approach for disease stratification. This study aimed to evaluate whether large-scale serum metabolite panel combined with apolipoprotein E (APOE) ε4 genotype status could distinguish AD from cognitively normal (CN) individuals within the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.

METHODS: Baseline data from 594 participants in ADNI (237 AD, 357 CN) were analyzed. High-resolution serum metabolomics (Biocrates MxP® Quant 500) and APOE genotype data were integrated into a machine learning framework. Feature selection was performed using LASSO regression followed by model training and evaluation using repeated cross-validation and a held-out test set. Sensitivity analyses included models adjusted for potential cofounders, and evaluation of progressively smaller metabolites.

RESULTS: A panel of 151 metabolites distinguished AD from CN with high accuracy (test-set AUC = 0.90). Addition of APOE to the panel further improved model performance (AUC = 0.91 versus AUC = 0.75 for APOE alone; DeLong test p < 0.001), achieving strong sensitivity (0.92), specificity (0.84), and negative predictive value (0.94). Formal DeLong testing confirmed significant improvement of the combined model relative to APOE-alone classification, while the incremental gain over metabolomics alone was modest but consistent. Key predictive metabolites included bile acids, ether-linked phosphatidylcholines, and acylcarnitines, which are associated with pathways related to lipid metabolism, mitochondrial function, and the gut-liver-brain axis. Sensitivity analyses demonstrated overall stability of the metabolomic signature across covariate adjustments and subgroup analyses.

CONCLUSION: Our findings reinforce and extend prior observations that systemic metabolic dysregulation accompanies Alzheimer's disease. The integration of standardized targeted serum metabolomics with APOE ε4 genotype provides complementary predictive information beyond established genetic risk factors and may serve as a complementary tool alongside state-of-the-art plasma biomarkers such as p-tau217 and GFAP. Although external validation in independent cohorts and longidinal prediction studies remain essential prerequisites, the present results demonstrate the potential utility of integrated metabolomics and genomics approaches for non-invasive AD risk stratification. ClinicalTrials.gov Identifier: NCT00106899 and related ADNI phases.

RevDate: 2026-11-17
CmpDate: 2026-11-17

Li WC, Tseng WH, YC Chang (2026)

Sex-stratified associations between the triglyceride-glucose index and urinary AD7c-NTP levels in adults: a cross-sectional study.

Annals of medicine, 58(1):2758993.

BACKGROUND: Insulin resistance has been implicated in Alzheimer-related neurodegenerative processes. The triglyceride-glucose (TyG) index is an accessible surrogate marker of systemic insulin resistance, whereas urinary Alzheimer-associated neuronal thread protein (AD7c-NTP) has been investigated as a potential non-invasive biomarker of neuronal injury. However, whether the TyG index is independently associated with urinary AD7c-NTP levels after accounting for relevant cardiometabolic factors remains unclear.

METHODS: This cross-sectional study included 4,879 adults who underwent health examinations between 2020 and 2023. Anthropometric, hemodynamic, biochemical, and urinary AD7c-NTP data were collected. Sex-stratified multivariable linear regression models were adjusted for age, mean arterial pressure, body mass index, waist circumference, LDL-C, HDL-C, and the TyG index.

RESULTS: Women had higher urinary AD7c-NTP concentrations than men despite having lower TyG index values. In unadjusted analyses, the TyG index showed a weak positive correlation with urinary AD7c-NTP concentrations in women but not in men. However, after multivariable adjustment for age, mean arterial pressure, body mass index, waist circumference, LDL-C, and HDL-C, the TyG index was not independently associated with urinary AD7c-NTP concentrations in either men (B = -0.060, 95% CI -0.421 to 0.300; p = 0.742) or women (B = 0.495, 95% CI -0.116 to 1.106; p = 0.112). Age and mean arterial pressure were positively associated with urinary AD7c-NTP concentrations in both sexes. The formal sex-by-TyG interaction was not statistically significant.

CONCLUSION: In this cross-sectional sample, the TyG index showed a weak unadjusted association with urinary AD7c-NTP concentrations in women, but this association was not significant after multivariable adjustment. No independent association was observed in men, and there was no statistically significant evidence of effect modification by sex. These findings should be considered exploratory and do not establish that the TyG index identifies individuals at increased risk of Alzheimer's disease or supports sex-stratified screening.

RevDate: 2026-11-17

Benyahia A, Araar IE, Bahi Azzououm A, et al (2026)

Structural MRI Morphometry Across the Alzheimer's Disease Spectrum: Classification and Generalization.

Biomedical physics & engineering express [Epub ahead of print].

Structural magnetic resonance imaging (MRI) provides quantitative measures of brain changes associated with Alzheimer's disease (AD), but reliable classification also depends on the evaluation protocol and performance across cohorts. This study assessed a morphometry-based approach for distinguishing cognitively normal (CN) participants, those with mild cognitive impairment (MCI), and those with AD. The primary cohort included 815 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI), with one screening MRI per participant and predefined training, validation, and test sets. MRI records were linked to FreeSurfer measurements using exact participant and image identifiers. A multinomial L2-regularized logistic regression classifier used 42 predefined structural features and five-fold cross-validation grouped by acquisition site. In the held-out three-class test (n = 121), balanced accuracy was 0.6119 (95% confidence interval [CI]: 0.5291-0.6873) and the macro-averaged area under the receiver operating characteristic curve (ROC-AUC) was 0.7525. Recall was 0.8529 for CN, 0.2931 for MCI, and 0.6897 for AD. Additional development analyses examined demographic and clinical variables separately from the primary MRI-only result. For the binary transfer experiment, a separate ADNI-trained CN-versus-AD model using 32 shared morphometric features achieved balanced accuracy of 0.8458 and ROC-AUC of 0.9016 in site-grouped out-of-fold evaluation. The fixed model was then tested without target-cohort tuning on 181 older participants from the Open Access Series of Imaging Studies (OASIS-1), grouped by Clinical Dementia Rating (CDR = 0 versus CDR > 0). External balanced accuracy was 0.6492 (95% CI: 0.5799-0.7158) and ROC-AUC was 0.7502. Because ADNI diagnoses and OASIS-1 CDR groups are not identical clinical endpoints, the external experiment was interpreted separately from the primary three-class analysis. The results demonstrate the value of reporting class-specific performance and independent-cohort evaluation when assessing structural MRI morphometry.

RevDate: 2026-11-17

Bernard PJ, Dufossez R, Maj M, et al (2026)

A telescoped Biginelli/CuAAC sequence for the synthesis of multitarget Dihydropyrimidinones showing antioxidant, calcium channel and cholinesterase inhibition capacity for Alzheimer's disease therapy.

Bioorganic chemistry, 185:110728 pii:S0045-2068(26)01264-2 [Epub ahead of print].

Herein, we report the design, synthesis, and biological evaluation of a new series of 27 dihydropyrimidinone (DHPM)-based multifunctional triazoles for Alzheimer's disease (AD). These compounds are multitarget-directed ligands (MTDLs) synthesized through the first sequential Biginelli/ Huisgen approach without isolation of the alkyne intermediate, providing rapid and efficient access to structurally diverse derivatives in accordance with several of the principles of green chemistry. Biological evaluation, including Ca[2+] channel activity, oxidative stress, and cholinesterase inhibition, revealed clear structure-activity relationships, mainly governed by the nature of the substituent attached to the triazole ring. At 10 μM in the SH-SY5Y depolarization assay, several compounds reduced Ca[2+] influx to an extent comparable to or greater than nimodipine under the same conditions, whereas triazoles bearing a 4-hydroxy-3-methoxybenzyl group exhibited the strongest antioxidant properties. Both the 4-hydroxy-3-methoxybenzyl and indole substituted triazoles displayed the most favorable hBuChE inhibition profile, the former being the most potent compounds. Among the series, compounds C17 and C26 emerged as the most promising MTDL, combining Ca[2+] channel-blocking activity, antioxidant properties, and measurable hBuChE inhibition. Overall, these results identify the DHPM-triazole-substituted scaffold as a promising platform for developing sustainable MTDL agents for AD.

RevDate: 2026-11-17

Han S, Sun M, Cui B, et al (2026)

Glucosyloxybenzyl succinate derivatives and related glycosides from Pleione yunnanensis with complementary effects on multiple Aβ1-42-associated processes.

Bioorganic chemistry, 185:110767 pii:S0045-2068(26)01303-9 [Epub ahead of print].

Alzheimer's disease (AD) is associated with dysregulated amyloid-β (Aβ) production, assembly, and oligomer-mediated neurotoxicity. The SCG fraction from the pseudobulbs of Pleione yunnanensis attenuated scopolamine-induced learning and memory impairment in mice. Subsequent phytochemical investigation of this bioactive fraction afforded 25 constituents, including nine previously undescribed glycosides (1-9) and 16 known compounds (10-25). Their structures were established by spectroscopic analysis, chemical hydrolysis, and comparison with reported data. The isolated compounds and selected related glycosides were evaluated in complementary Aβ1-42-centered assays, and the in vivo disposition of militarine was profiled in rat plasma and brain by LC-HRMS/MS. Among the tested compounds, compound 12 showed the most consistent activity at the tested concentrations, restoring SH-SY5Y cell viability to 99.03 ± 0.98% at 10 μM in the Aβ1-42 oligomer-enriched preparation-induced injury model, inhibiting Aβ1-42 aggregation by 61.64 ± 0.54% at 200 μM, and promoting fibril disaggregation by 48.74 ± 3.17% and 31.60 ± 0.76% at 200 and 20 μM, respectively. Other compounds displayed modest BACE1 inhibitory screening activity or detectable noncovalent interaction with Aβ1-42; compound 8 gave the highest relative binding ratio among the compounds reported here (30.10%). In the metabolism study, 21 militarine-related features were putatively assigned, with 19 detected in plasma and 9 in brain, including intact militarine (M0) and a predominant M7 signal putatively assigned to p-hydroxybenzyl alcohol. These findings define a chemically diverse Pleione glycoside series with complementary effects on Aβ1-42-associated processes in screening assays and provide preliminary exposure-related support for further investigation; they do not establish in vivo target engagement, compound synergy, or clinical efficacy.

RevDate: 2026-11-17

Macedo J, Almeida M, Ribeiro R, et al (2026)

Effects of temporal and parietal cortex non-invasive brain stimulation on memory in healthy older adults, mild cognitive impairment, and Alzheimer's disease: A systematic review and meta-analysis.

Neurobiology of aging, 170:103-119 pii:S0197-4580(26)00187-9 [Epub ahead of print].

Memory decline is a common cognitive complaint among healthy older adults, mild cognitive impairment (MCI) and Alzheimer's disease (AD). Non-invasive brain stimulation (NIBS) has been investigated as a promising approach for enhancing memory. While most studies target the dorsolateral prefrontal cortex, interest is growing in stimulating temporal and parietal areas due to their involvement in episodic and associative memory. This systematic review and meta-analysis evaluated the effects of temporo-parietal NIBS on memory in healthy older adults and patients with MCI and AD. Nineteen studies were included in the systematic review, of which 12 provided data for random-effects meta-analysis. Effects were expressed as Hedges' g, comparing active and sham stimulation. Overall, NIBS significantly improved memory performance (g = 0.67, 95% CI 0.27, 1.07). Analyses stratified by stimulation modality showed a significant effect for transcranial alternating current stimulation (tACS) (g = 0.81, 95% CI 0.08, 1.53), whereas repetitive transcranial magnetic stimulation (rTMS) did not reach statistical significance (g = 0.60, 95% CI -0.0003, 1.19). The difference between modalities was not significant (p = 0.54). Additional analyses showed significant improvements in episodic memory across healthy older adults and patients with MCI and AD (g = 0.60, 95% CI 0.19, 1.01) and in patients with MCI and AD alone (g = 0.61, 95% CI 0.17, 1.06). rTMS did not significantly improve episodic memory in MCI and AD (g = 0.62, 95% CI -0.08, 1.31). These findings suggest potential memory benefits, but substantial heterogeneity and very low certainty of evidence warrant cautious interpretation.

RevDate: 2026-11-17

Fang M, Su K, X Hu (2026)

Regulation mechanisms of Aβ1-42 protofibrils by chlorin e6 at two temperatures: A molecular dynamics simulation study.

Biophysical chemistry, 341:107734 pii:S0301-4622(26)00167-5 [Epub ahead of print].

β-amyloid (Aβ) protofibrils are closely associated with Alzheimer's disease. Extensive studies have employed molecular dynamics simulations to investigate the mechanistic behavior of Aβ1-42 protofibrils in the presence and absence of inhibitors. Chlorin e6 (Ce6), a natural photosensitizer with a unique chemical structure, has been applied to inhibit the aggregation of Aβ peptides and disrupt the stability of Aβ protofibrils. However, the molecular mechanism by which Ce6 destabilizes the Aβ1-42 protofibril remains elusive. In this study, we constructed the simulation systems of Aβ1-42 protofibrils interacting with Ce6 molecules and utilized all-atom molecular dynamics simulations at 300 K and 313 K to elucidate the early destabilization mechanisms. The results indicate that Ce6 molecules form stable interactions with Aβ1-42 protofibrils and cause local conformational destabilization of Aβ1-42 protofibrils under both temperature conditions. Furthermore, increasing the temperature from 300 K to 313 K significantly enhances the van der Waals and electrostatic interactions, which are the major contributors to the binding free energy. These interactions are favorable for the binding between Ce6 molecules and the Aβ1-42 protofibril, thereby destabilizing the conformation of Aβ1-42 protofibrils. This study provides a theoretical basis for developing the natural photosensitizer Ce6 as a potential therapeutic agent for disrupting Aβ1-42 protofibrils.

RevDate: 2026-11-17

Wu Q, Zhang J, Lu M, et al (2026)

DMM-Net: A dual-stage multimodal modulation network for Alzheimer's disease diagnosis.

Computer methods and programs in biomedicine, 289:109713 pii:S0169-2607(26)00462-1 [Epub ahead of print].

BACKGROUND: Alzheimer's disease (AD) typically progresses from cognitively normal (CN) to mild cognitive impairment (MCI) and eventually to AD. Due to the overlap of imaging manifestations and clinical indicators across different stages, accurate multi-class diagnosis remains challenging. Although structured clinical data can provide complementary information to imaging modalities, effective collaborative modeling between three-dimensional structural magnetic resonance imaging (3D sMRI) and structured clinical data remains insufficiently explored. This study aims to develop a cross-modal modulation approach for AD diagnosis.

METHODS: In this study, a Dual-stage Multimodal Modulation Network (DMM-Net) was proposed for AD cognitive state classification by integrating 3D sMRI and structured clinical data. The proposed framework consists of a Position-aware Clinical Spatial Modulation (PCSM) module, a transfer learning-based three-dimensional imaging feature extraction network MedNet, and a Feature-Clinical Cross-modal Modulation (FCCM) module. At the shallow stage, PCSM combines an image-derived spatial response with a subject-level clinical bias to modulate early imaging features. At deeper stages, FCCM jointly uses the intermediate Layer2 imaging representation and the clinical embedding to generate stage-specific calibration parameters for Layer3 and Layer4.

RESULTS: Experimental results on the ADNI dataset demonstrated the effectiveness of DMM-Net for the CN/MCI/AD three-class classification task. The combined PCSM-FCCM configuration achieved a BA of 75.1%, outperforming either module alone. Compared with the adapted HyperFusion baseline under the unified evaluation protocol, DMM-Net improved BA and precision by 9.0 and 7.7 percentage points, respectively. Post hoc Grad-CAM and SHAP analyses were used to characterize the imaging regions and structured clinical features associated with the model predictions.

CONCLUSION: The framework enhances joint modeling between 3D sMRI and structured clinical data through a coordinated dual-stage multimodal modulation mechanism, demonstrating its effectiveness for multimodal computer-aided classification of Alzheimer's disease under the evaluated setting.

RevDate: 2026-11-17

Zhang X, Yang J, Yu K, et al (2026)

A cell-type-resolved proteomic atlas reveals intra- and intercellular signaling in Alzheimer's disease.

Neuron pii:S0896-6273(26)00815-9 [Epub ahead of print].

Alzheimer's disease (AD) arises from pathological interactions among diverse brain cell types, but cell-type-specific proteomic changes remain underexplored. Here, we present deep proteomic profiling of sorted or proximity-labeled brain cells from AD mouse models (5xFAD and App[NL-G-F]) at multiple ages, quantifying 13,411 proteins in microglia, astrocytes, oligodendrocyte precursor cells, and neurons, with additional spatial information. We identified 3,028 differentially abundant proteins, most of which were absent in a bulk proteomic dataset, and constructed cell-type-specific networks to define functional modules and hub proteins. Comparison with transcriptomic data revealed that ∼30% of proteomic changes are RNA discordant. Further analyses uncovered cross-cell-type signaling proteins conserved in human AD brains, such as pleiotrophin (Ptn), which is transcriptionally enriched in astrocytes but accumulates in microglia. Importantly, recombinant PTN activates human induced microglia (iMG) cells. Thus, these findings provide a comprehensive cell-type-resolved proteomic atlas of AD models, highlighting novel intra- and intercellular signaling events.

RevDate: 2026-11-17

Matatall KA, Wathan TK, Nguyen M, et al (2026)

TET2-mutant myeloid cells mitigate Alzheimer's disease progression via CNS infiltration and enhanced phagocytosis in mice.

RevDate: 2026-11-17

Barr HJ, Caldwell SK, Colville-Reimertz JM, et al (2026)

Brain border-associated macrophages rhythmically scavenge amyloid-beta and regulate vascular amyloid pathology.

Immunity pii:S1074-7613(26)00438-3 [Epub ahead of print].

Circadian disruptions perturb the brain and immune system and increase the risk of developing Alzheimer's disease (AD), yet whether this involves dysregulation of brain immunity remains less clear. Here, we performed single-cell RNA sequencing of the brain immune compartment around the day-night cycle and identified brain border-associated macrophages (BAMs) as highly rhythmic cells. We found that the rest phase was a specialized time for BAM engulfment, characterized by upregulation of endocytic machinery and enhanced uptake of fluid-borne material including amyloid-beta (Aβ). Rhythmicity in BAM scavenging was regulated by the clock gene Bmal1, mediated by the scavenger receptor CD206, and perturbed with age. In a mouse model of AD, deletion of Bmal1 in BAMs worsened perivascular and leptomeningeal Aβ plaque burden. Our results characterize rapid endocytosis as a specialized and rhythmic BAM function and identify perturbed timing of brain border immunity as one avenue by which circadian disruptions may precipitate amyloidosis.

RevDate: 2026-11-17

Lin H, Huang Z, Liao Z, et al (2026)

Integrated Multi-Omics and Machine Learning for Prioritizing Candidate Plasma Proteins in Alzheimer's Disease and Predicting Multi-Target Interactions of Traditional Chinese Medicine.

Brain research bulletin pii:S0361-9230(26)00508-3 [Epub ahead of print].

This study integrated multi-omics data and machine learning to prioritize candidate plasma proteins and to predict the multi-target interactions of traditional Chinese medicine (TCM) in Alzheimer's disease (AD). Mendelian randomization across three cohorts (Icelandic, UK Biobank, and Fenland) identified 66 AD-associated plasma proteins, including TREM2, ACE, GRN, and CR1, with TREM2 showing a robust protective effect (OR = 0.78, 95% CI: 0.75-0.81). Single-cell RNA sequencing showed neuron-specific downregulation of NSF and TMEM106B in AD, implicating synaptic dysfunction and impaired axonal transport. A machine-learning classifier (K-nearest neighbors, KNN) incorporating TREM2, TMEM106B, C1S, PLOD2, and NSF, trained on brain-tissue expression data, demonstrated moderate predictive performance (AUC = 0.76, 95% CI: 0.63-0.90) and is presented as a candidate brain-tissue-derived classifier rather than a validated non-invasive plasma diagnostic panel. Immune infiltration analysis revealed altered M2 macrophage and plasma cell dynamics, with NSF negatively correlated with γδ T-cell infiltration (p < 0.001). Network pharmacology prioritized five candidate TCM herbs (e.g., Scutellaria baicalensis [Huang Qin] and Alpinia oxyphylla [Yi Zhi]) and bioactive compounds (stigmasterol and quercetin) targeting AD-related proteins. Molecular docking predicted strong binding between stigmasterol and PLOD2 (binding energy: -11.2kcal/mol), suggesting a potential role in modulating extracellular matrix remodeling. These compounds were enriched in the PI3K-Akt and NF-κB pathways, consistent with the anti-inflammatory effects observed in TCM formulations such as GHYSJ. These findings link candidate biomarker discovery with the predicted multi-target interactions of TCM, providing hypotheses for future non-invasive diagnosis and precision therapy in AD.

RevDate: 2026-11-17

Charvet CJ, J Sun (2026)

Translating Time Across Species: Optimizing Rodent Models for Neurological Disease Research.

Brain research bulletin pii:S0361-9230(26)00515-0 [Epub ahead of print].

Rats and mice are widely studied to inform human diseases. However, there are important biological differences between humans and rodents. For example, humans progress through development and aging much more slowly than rodents. The compressed timescale of rodent development and aging creates challenges to translate findings from rodents to humans. We draw insights from the Translating Time research project, which is a long-term project that integrates thousands of biological and behavioral measures to establish age equivalences across different species. We discuss how to align ages between humans and mice and rats in the context of developmental (e.g., spinal muscular atrophy, autism) and age-related disorders (e.g., Alzheimer's disease). Age is an important factor to consider in the selection of a model. For example, assuming age-related dementia rates are similar in humans and mice, few mice live to develop dementia once their ages are merged onto a common template. Examples such as these show that mice models are well suited for some diseases but may be limited to study others, especially for those that occur a geriatric stages of life. Finally, we discuss how a One Health approach can complement laboratory research to advance biomedicine.

RevDate: 2026-11-17

Liu DY, Zhang F, Ding K, et al (2026)

Bidirectional interplay of the gut microbiota and herbal medicine in Alzheimer's disease: mechanisms and therapeutic prospects.

Journal of ethnopharmacology pii:S0378-8741(26)01474-1 [Epub ahead of print].

Alzheimer's disease (AD) is a progressive neurodegenerative disorder in which alterations in the gut microbiota and microbiota-gut-brain axis (MGBA) may contribute to disease-related pathological processes. Herbal medicines have long been used for memory impairment and age-related cognitive disorders and contain bioactive constituents with diverse molecular targets. Increasing evidence suggests that herbal interventions can modulate the gut microbiota, while gut microorganisms can biotransform selected herbal constituents and influence their absorption and biological activity. These reciprocal interactions provide a mechanistic basis for investigating herbal medicine in AD.

AIM OF THE REVIEW: This review summarizes the bidirectional interactions between herbal medicine and the gut microbiota in AD, focusing on microbial composition and metabolites, intestinal barrier function, herbal biotransformation and bioavailability, signaling pathways, and multi-omics approaches.

MATERIALS AND METHODS: A structured narrative literature review was conducted using PubMed, Web of Science, and ScienceDirect for studies published from January 2010 to June 2026. Google Scholar searches and reference-list screening supplemented the database searches. Human, animal, and in vitro studies concerning AD, gut microbiota, herbal interventions, microbial metabolites, biotransformation, and bioavailability were included according to predefined eligibility criteria.

RESULTS: Herbal formulas, extracts, and compounds have been reported to alter gut microbial composition and metabolite profiles, improve intestinal barrier integrity, and influence inflammatory, oxidative, amyloid-β (Aβ)-related, and synaptic pathways relevant to AD. Conversely, the gut microbiota can biotransform selected herbal constituents, thereby altering their absorption and pharmacological properties. Integrated microbiome-metabolome studies also link microbial taxa, metabolites, and host signaling pathways, but most findings remain preclinical or correlational.

CONCLUSIONS: The bidirectional interaction between herbal medicine and the gut microbiota may be relevant to AD treatment. However, current evidence is largely preclinical and clinical validation remains limited. Future studies should clarify microbiota-dependent biotransformation and pharmacokinetics, standardize herbal formulas and dosing, establish causal microbe-metabolite-host relationships, assess long-term safety and herb-drug interactions, and conduct rigorous clinical trials before translation into AD management.

RevDate: 2026-11-15

Mecca AP (2026)

Considering evoke and evoke+ outcomes for future Alzheimer's disease drug development.

RevDate: 2026-11-15

Zhen Y, Zhang K, Li S, et al (2026)

The disrupted navigational compass: pathophysiological mechanisms and clinical interventions for spatial navigation deficits.

Neuroscience and biobehavioral reviews pii:S0149-7634(26)00551-8 [Epub ahead of print].

Spatial navigation is a higher-order integrative cognitive ability that supports environmental orientation, goal-directed route selection, and adaptive locomotion by integrating spatial memory, multisensory cues, attention, and executive control. Neural systems supporting navigation are also vulnerable to aging and neurodegenerative disease, making navigation a useful domain for linking basic mechanisms with clinically measurable functional impairment. This review summarizes spatial-navigation mechanisms across multiple levels. At the cognitive level, navigation depends on interacting processes including spatial representation, path integration, reference-frame transformation, landmark use, and route planning. At the network level, hippocampal-entorhinal, retrosplenial-parietal, scene-selective, and prefrontal systems contribute complementary functions. At the cellular level, place-, grid-, head-direction-, speed-, and boundary-related representations encode position, heading, self-motion, environmental geometry, and prospective behavior. Clinical and neuroimaging studies indicate that navigation impairment is associated with structural and functional abnormalities, with the strongest diagnostic evidence currently arising from Alzheimer's disease and its prodromal stages. VR-based behavioral assessment and electrophysiological approaches provide complementary means of characterizing navigation phenotypes: VR enables controlled, repeatable, process-sensitive tasks, whereas intracranial and scalp recordings provide neural information at different spatial and physiological scales. No pharmacological agent has been developed or licensed specifically for navigation impairment; current navigation-focused interventions therefore rely mainly on behavioral and VR-based rehabilitation, compensatory strategies, and emerging neuromodulation approaches. Future studies should integrate process-specific behavioral and physiological markers with biomarker-defined clinical cohorts, and use large, randomized, longitudinal studies to establish diagnostic validity, real-world transfer, and mechanism-informed intervention effects.

RevDate: 2026-11-15
CmpDate: 2026-11-15

Sharma A, Singh G, Mannan A, et al (2026)

Toll-Like Receptor-Driven Neuroinflammation in Neurological Disorders: Signaling Crosstalk and Therapeutic Opportunities.

Journal of neuroscience research, 104(11):.

Toll-like receptors (TLRs) serve as pivotal mediators bridging innate immunity and neuroinflammation, orchestrating pathological cascades that drive neurological disorders. Beyond their sentinel role in pathogen recognition, aberrant TLR activation triggers intricate and destructive signaling networks, including activation of NF-κB, MAPK, JAK/STAT, and PI3K/AKT, alongside IRFs and type I interferon responses that converge on chronic neuroinflammation and subsequent neuronal damage. This review dissects TLRs' multilayered contribution to neuropathology, emphasizing their regulation of secondary inflammatory mechanisms, including NLRP3 inflammasome priming and activation, mTOR-driven metabolic dysregulation, SOCS-mediated feedback inhibition, inflammasome activation, and pyroptotic cell death. Critically, these signaling pathways create a pathological intersection with oxidative stress and mitochondrial dysfunction, amplifying a self-perpetuating cycle of neuronal injury that underlies conditions like Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and Amyotrophic lateral sclerosis (ALS), Stroke, Multiple sclerosis (MS), Epilepsy and Traumatic brain injury (TBI). Against this neuropathological landscape, this review systematically evaluates emerging therapeutic strategies targeting TLR-mediated neuroinflammation, encompassing small molecule TLR antagonists, intracellular adaptor protein inhibitors targeting myeloid differentiation primary response 88 (MyD88) and TIR-domain-containing adapter-inducing interferon-β (TRIF), biologic therapies including monoclonal antibodies and fusion proteins, natural phytochemicals and nutraceuticals, Clustered regularly interspaced short palindromic repeats (CRISPR)-based genomic interventions, and cell-based immunomodulatory therapies, collectively representing a mechanistically diverse arsenal aimed at recalibrating the dysregulated innate immune response to achieve durable neuroprotection across the full spectrum of TLR-mediated neurological disorders.

RevDate: 2026-11-15
CmpDate: 2026-11-15

Cai WJ, Xie YJ, Liu XR, et al (2026)

[Research progress on early biomarkers of Alzheimer's disease].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 60(11):1854-1861.

As the global population continues to age, Alzheimer's disease (AD) has become a serious public health issue. Compared to traditional diagnostic methods, blood biomarkers offer new avenues for early AD screening due to their advantages, such as low invasiveness and high throughput. In 2024, the National Institute on Aging-Alzheimer's Association (NIA-AA) updated its ATN biomarker research framework, in which A, T, and N denote β-amyloid, tau, and neurodegeneration (hereafter the ATN framework), formally establishing the diagnostic status of blood biomarkers and proposing Core 1 and Core 2 biomarkers for disease diagnosis and pathological staging; and atypical biomarkers, such as those related to neurodegeneration, inflammation, vascular damage, and comorbid proteins, to reflect mixed pathological states. Although these markers show substantial potential for early AD screening, their clinical translation is still limited by insufficient standardisation across assay platforms and by assay interference. This review summarises recent advances in early AD biomarkers and outlines the challenges and prospects for their translation.

RevDate: 2026-11-15
CmpDate: 2026-11-15

Salari A, Taheri M, Khalili M, et al (2026)

Simvastatin Alleviation of Trimethyltin-Induced Hippocampal and Behavioral Impairments via Improvement of Antioxidants, Mitochondrial Health, and Energy Homeostasis.

Pharmacology research & perspectives, 14(6):.

Mitochondrial dysfunction and antioxidant deficiency are key contributors to the pathogenesis of Alzheimer's disease (AD). Trimethyltin (TMT) induces selective hippocampal damage associated with redox disequilibrium, neuroinflammatory responses, mitochondrial dysfunction, and impaired energy homeostasis, leading to cognitive decline. The present study evaluated whether simvastatin as a lipid-lowering and protective medicine could mitigate TMT-induced behavioral abnormalities by improving hippocampal antioxidant status, mitochondrial integrity, and energy homeostasis. Rats were assigned to control, control + simvastatin (30 mg/kg), TMT, TMT + simvastatin (10 mg/kg), and TMT + simvastatin (30 mg/kg) groups. TMT was injected IP (once, 8 mg/kg) to instigate neurotoxicity. Following three weeks of treatment, locomotor activity and conditioned learning and memory deficits were analyzed using open-field and passive avoidance tests, respectively. Besides, hippocampal levels or activity of nitrite, glutathione (GSH), glutathione peroxidase (GPx), myeloperoxidase (MPO), and β-site APP-cleaving enzyme 1 (BACE1), mitochondrial membrane potential (MMP), and AMP-activated protein kinase (AMPK) were measured. Simvastatin treatment (30 mg/kg) was associated with higher latency in the passive avoidance test and longer rearing in the open field test in TMT-intoxicated rats. Additionally, simvastatin improved hippocampal GSH, GPx, MMP, and AMPK and mitigated MPO activity relative to the TMT group but did not significantly affect nitrite or BACE-1 activity. Collectively, simvastatin mitigated TMT-induced neurobehavioral impairment, partly through restoration of antioxidants and mitochondrial health in association with AMPK.

RevDate: 2026-11-16
CmpDate: 2026-11-15

Suo X, Feng Q, Lu H, et al (2026)

Protective effects of rs7315280 on hippocampal volume and cognitive decline in aging by its enhancer activity regulating TESC expression.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 47(12):.

BACKGROUND: Hippocampal atrophy is a core biomarker of Alzheimer's disease (AD), yet the cognitive relevance and molecular function of its genetic determinants remain largely unknown. In this study, we aimed to bridge this critical gap by systematically identifying and functionally characterizing a key genetic determinant of hippocampal volume and its role in AD.

METHODS: We performed a cross-cohort Genome-wide association studies (GWAS) meta-analysis using data from UK Biobank (n = 33,731) and ENIGMA (n = 26,814). Phenotypic associations were validated in the ADNI-1 cohort (n = 756), adjusting for polygenic risk scores (PRS). Functional characterization included in silico annotation (3DSNP/ENCODE), dual-luciferase reporter assays, and brain-specific eQTL analysis.

RESULTS: We identified rs7315280 (A > G) as a lead genetic variant associated with hippocampal volume via meta-GWAS analysis (all P ≤ 1.37 × 10[-19]). In ADNI-1, G allele carriers had larger hippocampal volumes (P = 0.004), a lower AD conversion rate (3%), delayed disease onset (P = 0.015), and an odds ratio for AD of 0.663. rs7315280 localizes to hippocampal enhancer regions and binds 51 transcription factors (e.g., CTCF). The G allele enhanced transcriptional activity (P = 0.002), and rs7315280 was linked to TESC expression in the human prefrontal cortex (P = 1.30 × 10⁻[5]).

CONCLUSIONS: Our findings suggest that rs7315280 may contribute to protection against AD by acting as an enhancer regulating TESC expression, identifying a potential novel genetic locus and a candidate therapeutic target for further investigation.

RevDate: 2026-11-15

Tschui V, Pugeda T, Swierczek U, et al (2026)

CD22 loss enhances phagocytosis in myeloid cells and ameliorates Alzheimer's disease-like pathology in mice.

The EMBO journal [Epub ahead of print].

CD22, an inhibitory receptor canonically expressed in B cells, is also present in microglia of the murine central nervous system. In the human brain, CD22 was predominantly found in oligodendrocytes, but also in a subset of brain-resident myeloid cells from patients with Alzheimer's disease, while it is also expressed in peripheral monocytes and differentiated THP-1 cells. CD22 has been implicated as a negative regulator of microglial phagocytosis. Here, we demonstrate that genetic ablation of CD22 in APPPS1 transgenic mice, a widely used murine model of Alzheimer's disease-like pathology, attenuates amyloid-β pathology and protects parvalbumin-positive interneurons in an age-dependent manner. Mechanistically, microglia and differentiated THP-1 cells lacking CD22 exhibit enhanced activation and phagocytosis following stimulation of the pattern-recognition receptor CLEC7A, mediated by increased SYK signaling. Conversely, activation of CD22 with the agonistic antibody epratuzumab suppresses activation of differentiated THP-1 cells. Our findings identify a CLEC7A-CD22-SYK signaling axis in both human and murine myeloid cells, in which CD22 functions as an inhibitory regulator of CLEC7A-mediated cell activation.

RevDate: 2026-11-15
CmpDate: 2026-11-15

Varshavskaya KB, Barykin EP, Korokin MV, et al (2026)

Tetrapeptide НАЕЕ Inhibits the Toxic Effect of Beta-Amyloid on NEURO2A Neuroblastoma Cells.

Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 529(1):244-247.

Alzheimer's disease (AD) is characterized by the accumulation of beta-amyloid (Aβ), which plays a key role in the pathogenesis of the disease. Levels of the tetrapeptide HAEE, an endogenous component of human blood, are significantly reduced in AD patients. In this study, we demonstrated that HAEE protects Neuro2a cells from the cytotoxic effects of Aβ by preventing necrosis, apoptosis, and the decline in mitochondrial potential, as well as by reducing Aβ internalization. These findings demonstrate the potential of HAEE as a therapeutic agent for the treatment of AD.

RevDate: 2026-11-15
CmpDate: 2026-11-15

Koltunova LA, Zaripov PI, Mkhitaryan EA, et al (2026)

Increase in IgM Autoantibodies to Aβ1-42 in Plasma of Men with Alzheimer's disease.

Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 529(1):278-281.

The pathogenesis of Alzheimer's disease (AD) is associated with impaired metabolism of the beta‑amyloid peptide (Aβ), which acts not only as a pathogenetically significant factor but also as a potential autoantigen capable of inducing a humoral immune response. In contrast to IgG antibodies to Aβ, which have been studied quite extensively, the levels of IgM antibodies to this peptide in AD patients and healthy donors remain poorly investigated. In the present study, we performed a comparative evaluation of IgM titers to Aβ1-42 in the peripheral blood plasma of 26 AD patients and 26 healthy donors using enzyme‑linked immunosorbent assay (ELISA). The obtained data demonstrate a statistically significant elevation of IgM antibody titers to Aβ1-42 in the plasma of men with AD compared to the healthy donor group.

RevDate: 2026-11-15
CmpDate: 2026-11-16

Shi S, W Liu (2026)

Lost balance: synergy-redundancy dysfunction in Alzheimer's disease.

BMC geriatrics, 26(1):.

Alzheimer's disease (AD) is the most common neurodegenerative disorder, yet reliable early biomarkers are still lacking, which greatly hinders timely intervention for AD. This study employed an integrated information decomposition framework to systematically investigate the dynamic evolution of brain synergy and redundancy information in different AD stages and their associations with cognitive function, aiming to explore potential novel biomarkers for AD early diagnosis. The results show that, compared with the cognitively normal (CN) group, the cognitively abnormal (CA) group exhibited a distinct pattern of enhanced synergy and reduced redundancy. This pattern difference is primarily distributed within the default mode network (DMN), and is significant even in early-stages of AD, indicating that synergy-redundancy information is a promising biomarker for AD early diagnosis. Despite the inclusion of cognitively impaired individuals, functional decoding analyses still revealed that synergy mainly supported higher-level cognitive and social functions, whereas redundancy was more related to sensorimotor and basic cognitive functions. Additionally, compared to the CN group, the CA group exhibited stronger positive synergy correlations in brain regions related to working memory and cognitive control, possibly reflecting compensatory mechanisms, while negative synergy correlations were observed in pain-processing regions, potentially linked to impaired sensory perception. Stronger positive redundancy correlations in motor-related regions but negative correlations in reward-related regions, may suggest AD-related selective reorganization of information processing. Finally, a machine learning model constructed based on synergy-redundancy information demonstrated superior performance in AD stage classification, providing new insights for AD early diagnosis and further validating the potential of synergy-redundancy information as early biomarkers.

RevDate: 2026-11-15
CmpDate: 2026-11-16

Jiang Y, Albornoz EA, Zheng H, et al (2026)

Inflammation-associated serum amyloid A amplifies amyloid-β-driven oxidative stress and microglial activation.

Journal of neuroinflammation, 23(1):.

Systemic inflammation is increasingly recognised as a key modifier of Alzheimer's disease (AD) progression, yet the mechanisms linking inflammatory acute-phase responses to Amyloid-β (Aβ)-driven neurotoxicity remain incompletely defined. Here, we report that amyloidogenic acute-phase peptide fragment SAA19-45 (SAA27), derived from Serum Amyloid A (SAA), modulates Aβ aggregation and amplifies downstream oxidative and inflammatory stress responses in neuronal and microglial systems.Immunofluorescence analysis of human AD brain tissue revealed plaque-associated SAA-positive cellular structures within or adjacent to Aβ-positive pathological microenvironments across all range of Braak stages. In vitro, co-incubation of SAA27 with Aβ accelerated Thioflavin T-positive aggregation kinetics and altered fibrillar organisation. In SH-SY5Y neurons, Aβ induced marked cytotoxicity and oxidative stress, and SAA27 selectively enhanced intracellular reactive oxygen species without a proportional increase in cell death. In HMC3 microglia, Aβ triggered oxidative stress and inflammatory activation, both of which were further amplified by SAA27, as reflected by increased reactive oxygen species and elevated IL-6 secretion. Similarly, SAA27 enhanced Aβ-induced IL-1β release in monocyte-derived microglia-like cells. In zebrafish larvae, Aβ and SAA27 co-injection produced a stronger ThT-positive amyloid signal and synaptic degeneration, compared with Aβ alone, supporting enhanced amyloid accumulation and synaptic disruption in vivo. Quantitative proteomics revealed Aβ-driven stress and proteostasis-related reprogramming in both neurons and microglia, with SAA27 biasing these responses toward oxidative and activation-associated pathways consistent with microglial remodelling and immune engagement. The polyphenol epigallocatechin gallate (EGCG) suppressed fibrillar aggregation in vitro and in zebrafish larvae, preserved synaptic integrity in vivo, attenuated oxidative and inflammatory responses, and differentially modulated cellular proteomic states, promoting near-restoration in neurons while inducing a distinct, less stress-associated state in microglia.Together, these findings identify SAA27 as an inflammation-associated co-factor that accelerates Aβ assembly and amplifies oxidative and innate immune stress responses. The observed partial overlap with human AD proteomic signatures further supports the disease relevance of these pathways. This work provides mechanistic insight into how systemic inflammatory states may exacerbate amyloid-driven neuroinflammation in AD and highlights inflammation-amyloid crosstalk as a pharmacologically modifiable axis.

RevDate: 2026-11-15

Qiu Z (2026)

Recombinant AAV-Based Gene Therapy for Central Nervous System Disorders: From Gene Replacement to Precision Editing and Circuit Modulation.

Human gene therapy [Epub ahead of print].

Recombinant adeno-associated virus (rAAV) vectors have moved central nervous system (CNS) gene therapy from experimental proof of concept to clinically validated treatment, yet therapeutic design remains highly dependent on disease mechanism, cellular distribution, and treatment timing. This narrative review examines recent progress in rAAV-based interventions for neurodevelopmental disorders (NDDs) and neurodegenerative disorders. For monogenic NDDs, gene replacement is most applicable to loss-of-function conditions with compatible payload size and tolerable expression, whereas dominant-negative, gain-of-function, and dosage-sensitive disorders may require allele-selective silencing or precise DNA or RNA editing. Rett syndrome illustrates both the reversibility of postnatal dysfunction and the need for tightly regulated transgene expression. Spinal muscular atrophy provides the leading translational paradigm: rAAV9-mediated SMN1 replacement demonstrates the value of early diagnosis, adequate tissue exposure, and treatment before irreversible neuronal loss. For complex neurodegenerative diseases, emerging strategies extend beyond simple gene addition. APOE-directed editing and protective-variant replacement may enable genotype-informed intervention in Alzheimer's disease, whereas Parkinson's disease programs combine restoration of dopamine synthesis, neuroprotection, and genetically encoded circuit modulation. Across these indications, major barriers include incomplete and nonselective CNS delivery, immune and dose-related toxicity, limited redosing, durable control of transgene or editor activity, off-target effects, and uncertain translation from animal models to humans. Progress over the next decade will depend on human-compatible vectors, cell-selective and regulatable expression, rigorous long-term safety assessment, biomarker-guided trials, and rational combinations that connect molecular target engagement to meaningful neurological benefit.

RevDate: 2026-11-15
CmpDate: 2026-11-16

Abubakar M, Giri A, Goel F, et al (2026)

Corrigendum to: Diabestes, Alzheimer's Disease Risk Factors, and the Cafeteria Diet: A Comprehensive Review.

Current neuropharmacology, 24(12):1984.

We have identified that reference numbers 81 and 93 in the published version of this article [1] were inadvertently published incompletely. Details of the error and the correction are provided below: ORIGINAL [81] Hughes, E. Gut health: Efficacy of supplementation when it comes to IBS. 2020. Available from: [93] Desmet, L. Tuning feeding time to prevent the effects of chronodisruption in the gut induced by chronic jetlag. 2022. Available from: CORRECTED [81] Hughes, E. Gut health: Efficacy of supplementation when it comes to IBS. 2020. [93] Desmet L. Tuning feeding time to prevent the effects of chronodisruption in the gut induced by chronic jetlag [dissertation on the Internet]. Leuven (BE): KU Leuven; 2022. Available from: https://lirias.kuleuven.be/handle/20.500.12942/689311 The original article has been updated accordingly. This corrigendum is published to ensure transparency and accuracy of the scholarly record. The corrected version of the article is available online at: https://www.eurekaselect.com/article/149266. The authors regret these errors and apologise for any inconvenience they may have caused.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Abgueguen E, Henriques A, Callizot N, et al (2026)

Sephin1 protects from glutamate stress, consistent with negative allosteric modulation of GluN2B-containing NMDA receptor.

Biochemistry and biophysics reports, 48:102879.

Glutamate excitotoxicity and GluN2B containing N-methyl-d-aspartate receptors (NMDARs) are involved in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Parkinson disease and Alzheimer disease. Recently, Sephin1, a first-in-class, multi-functional, brain-penetrant, orally administered small molecule, has been demonstrated in vitro to improve motor neurons survival following glutamate intoxication. In ALS animal models, Sephin1 was able to reduce motor neuron loss, to improve motor function and increase animal survival. To determine how Sephin1 can reduce motor neurons loss following glutamate intoxication, calcium flux was measured in primary cortical neurons and in GluN1A/GluN2B overexpressing cells following NMDA stimulation. Then, to determine the binding site on GluN1 and GluN2B subunits, binding assays were performed with three benzylideneaminoguanidine derivatives, Sephin1, guanabenz and IFB-048. Here, for the first time, we show that Sephin1 reduces calcium flux in NMDA stimulated primary cortical neurons in a dose dependent manner. Sephin1, guanabenz and IFB-048 reduce the rise of calcium flux in GluN1A/GluN2B subunits overexpressing cells stimulated with NMDA. In addition, we demonstrated that Sephin1, guanabenz and IFB-048, displace ifenprodil from the N-terminal domain (NTD) of NMDAR (GluN1/GluN2B) containing the polyamine site on GluN2B subunits. The three benzylideneaminoguanidine derivatives could possibly be Negative Allosteric Modulator (NAM) of GluN2B-containing NMDARs.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Han C, Z Guo (2026)

Neuroimaging of Anxiety in Mild Cognitive Impairment: Integrating Structural, Functional, Molecular, and Network Perspectives-A Narrative Review.

International journal of general medicine, 19:651366.

This narrative review summarizes neuroimaging evidence on the neurobiological correlates of anxiety symptoms in mild cognitive impairment (MCI) across the Alzheimer's disease continuum. A literature search was conducted in PubMed from 1 January 2015 to 30 June 2026. Structural magnetic resonance imaging studies link anxiety to atrophy in medial temporal and prefrontal-limbic regions, with white matter disruption in the cingulum bundle and uncinate fasciculus. Functional magnetic resonance imaging shows altered interactions among the default mode network, salience network, and central executive network. Molecular imaging points to limbic glucose hypometabolism, amyloid deposition, and neuroinflammation. Emerging vascular and peripheral biomarker data further implicate blood-brain barrier disruption and gut-brain axis alterations. Most of the literature is cross-sectional and relies on heterogeneous anxiety assessments. Findings are further complicated by symptom overlap with depression and other neuropsychiatric manifestations, and anxiety-specific imaging studies in MCI are relatively scarce. Direct evidence specific to anxiety in MCI remains limited; some findings discussed here are derived from studies of Alzheimer's disease dementia or general neuropsychiatric symptoms and should be interpreted accordingly. Longitudinal multimodal designs, standardized anxiety-specific instruments, and integrative models linking symptom dimensions to imaging and fluid biomarkers are needed to disentangle whether anxiety in MCI represents an early marker of neurodegeneration, a disease-course modifier, or both.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Mohammadi L, Roghani M, T Baluchnejadmojarad (2026)

Linagliptin as a Multi-Target Neuroprotective Agent in Cognitive Disorders: Molecular Mechanisms and Translational Challenges-A Narrative Review.

Drug design, development and therapy, 20:645071.

Cognitive disorders, which are characterized by progressive impairment of memory, language, and other cognitive functions, are a growing global health challenge. Currently, there are limited therapeutic options available to prevent or reverse the progression of these disorders. Linagliptin, an approved treatment for type 2 diabetes, has recently emerged as a neuroprotective agent, offering benefits beyond its glucose-lowering effects. Preclinical studies have demonstrated that linagliptin improves cognitive performance and protects neuronal integrity in various experimental models, including Alzheimer's disease (AD), Parkinson's disease (PD), cerebral ischemia, diabetic cognitive dysfunction, demyelination, and toxicant-induced cognitive impairment. The neuroprotective actions of linagliptin are mediated through multiple mechanisms, including the attenuation of endoplasmic reticulum (ER) stress, mitochondrial dysfunction, neuroinflammation, and oxidative stress, as well as the inhibition of apoptotic pathways, preservation of blood-brain barrier (BBB) integrity, and enhancement of neurovascular function. This multi-target profile highlights the potential of linagliptin as a promising therapeutic candidate for cognitive disorders. Despite encouraging preclinical findings, the CARMELINA and CAROLINA-COGNITION trials found no significant cognitive benefit of linagliptin, highlighting the gap between preclinical evidence and demonstrated clinical efficacy. This narrative review summarizes the molecular mechanisms and preclinical and clinical evidence regarding the effects of linagliptin in cognitive disorders, with particular emphasis on its potential neuroprotective mechanisms and translational challenges.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Hao J, Zhang J, Li Q, et al (2026)

Molecular Mechanisms of Nanoparticle-Mediated Targeted Drug Delivery in Neurodegenerative Diseases.

International journal of nanomedicine, 21:651672.

With global population aging, the incidence of neurodegenerative diseases continues to rise, and the blood-brain barrier (BBB) excludes approximately 98% of small-molecule drugs and nearly all large-molecule biologics from the central nervous system (CNS), so conventional small-molecule pharmacotherapy is largely limited to symptom modulation. Nanodrug delivery systems, including ligand-engineered polymeric, lipid, and inorganic nanoparticles as well as naturally secreted extracellular vesicles, have been proposed as a way to overcome the BBB and modulate disease pathways, and most of the supporting evidence currently derives from rodent models. This review synthesizes the molecular mechanisms by which these systems cross or bypass the BBB, summarizes representative disease-specific interventions in Alzheimer's, Parkinson's, Huntington's, amyotrophic lateral sclerosis, and multiple sclerosis, and critically discusses translational bottlenecks, with the explicit aim of distinguishing established mechanisms from preclinical observations and clarifying the path to clinical investigation. We deliberately limited in scope to systems for which mechanistic and delivery data are available, and the rapid pace of the field means that conclusions about clinical efficacy cannot be drawn from the present preclinical literature. Nevertheless, it still provides valuable insights for research in this field.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Bedel A, Bouaziz-Amar E, Bousiges O, et al (2026)

[The blood biomarker breakthrough in Alzheimer's disease: what applications in 2026? Part II: Emerging blood biomarkers, prospects and current limitations].

Annales de biologie clinique, 84(5):457-479.

This review highlights emerging blood-based biomarkers for Alzheimer's disease (AD) beyond the amyloid and Tau markers currently entering clinical practice. These biomarkers reflect multiple pathophysiological mechanisms involved in AD, including astroglial activation, genetic susceptibility, neuroinflammation, synaptic dysfunction, and neuronal plasticity. The clinical utility of measuring blood levels of GFAP, ApoE4, Apoε4, sTREM2, BDNF, inflammatory cytokines and beta-synuclein in Alzheimer's disease is discussed. Despite encouraging results, none of these biomarkers alone possesses sufficient diagnostic and prognostic value. Further development or their combination into panels will need to be evaluated to determine their potential future use in diagnosis, patient stratification or even therapeutic monitoring in patients with Alzheimer's disease.

RevDate: 2026-11-16

Fan C, Li B, S Wang (2026)

Human milk oligosaccharides as immunomodulators of the gut-immune-brain axis: a potential route to suppressing neuroinflammation in Alzheimer's disease.

Nutritional neuroscience [Epub ahead of print].

BACKGROUND: Alzheimer's disease (AD), the most common cause of dementia, is characterized by interacting pathological processes in which chronic neuroinflammation plays a central role. The gut-brain axis connects intestinal and central nervous system function through immune, neural, and metabolic pathways, yet how immune signaling integrates these pathways in AD remains unclear. Human milk oligosaccharides (HMOs) are structurally diverse bioactive glycans whose immunomodulatory properties extend beyond their prebiotic effects. This narrative review examines HMOs within a gut-immune-brain framework, proposing that neuroinflammation amplifies the interplay between gut-derived immune signals, amyloid-β and tau pathology, and neurodegeneration.

METHODS: Relevant literature was retrieved from PubMed, Web of Science, and Scopus through January 2026. The review focused on English-language publications from 2010 onward, supplemented by earlier foundational studies that provided essential mechanistic or historical context.

RESULTS: We synthesize evidence on immune communication along the gut-brain axis and examine how HMOs may influence this communication through microbiota-dependent effects and direct interactions with immune receptors. Particular attention is given to the relationships between HMO structure, receptor engagement, immune cell responses, and inflammatory signaling. These mechanisms provide a rationale for investigating whether HMOs can modify peripheral immune signals that contribute to neuroinflammation in AD. Throughout the review, findings from infant and other experimental settings are distinguished from evidence directly relevant to aging and AD.

CONCLUSION: Research on HMOs in aging and AD remains insufficient: direct evidence from aged or AD models is scarce, human trials are lacking, infant physiology differs substantially from that of older adults, and the bioavailability of HMOs to the aged brain is still uncertain. We therefore delineate this translational gap and outline research strategies to address it. Collectively, this review provides a conceptual framework for understanding the potential immunoregulatory roles of HMOs in neuroinflammation and identifies them as a hypothesis-generating class of candidate immunomodulators for AD.

RevDate: 2026-11-16

Xu S, Wang Q, Zhou Y, et al (2026)

SVP Maps Spatially Variable Functional Programs and Their Coupling in Spatial Transcriptomics.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) pii:e78741 [Epub ahead of print].

Spatial transcriptomics has made tissue architecture measurable at molecular resolution, yet most computational methods still identify spatially variable genes and infer biology only indirectly. We present SVP, a framework that directly maps spatially variable cell states, pathways and regulatory programs from spatial transcriptomic data. SVP combines location-level functional activity inference with global and local spatial autocorrelation and extends these analyses to bivariate spatial coupling across heterogeneous features. Across simulations and real datasets, SVP recovered cell-state-associated activity patterns at individual captured locations, detected spatially variable features with calibrated statistics, and scaled efficiently to large datasets. In pancreatic ductal adenocarcinoma, SVP identified a spatially co-organized hypoxic and extracellular-matrix-remodeling niche that co-localized with regions of low immune activity. It further captured functional maturation in the developing human heart and plaque-associated glial programs in Alzheimer's disease models. SVP enables direct analysis of functional spatial organization, moving beyond gene-centric descriptions of tissue structure.

RevDate: 2026-11-16

Grant JG, Hunter JM, McMillan TM, et al (2026)

Comparing multivariate cognitive change in unimpaired older adults to those with questionable impairment or mild dementia: a NACC study.

Journal of clinical and experimental neuropsychology [Epub ahead of print].

INTRODUCTION: We explored how frequently unimpaired older adults show declines across multiple cognitive measures and examined the extent to which their rates of multivariate cognitive change compared to older adults with questionable impairment or mild dementia.

METHOD: Two-year change scores were calculated for 1208 participants in the National Alzheimer's Coordinating Center (NACC) database. The number of declines in performance falling below the 5[th] percentile in the natural distribution of change scores (the total change count) among the unimpaired participants (n = 742) was compared to those with questionable impairment (n = 389) and those with mild dementia (n = 77).

RESULTS: Only 9.9% of the cognitively unimpaired participants obtained two or more significant declines in performance, compared to 27.5% of the questionably impaired participants and 49.4% of those with mild dementia. The total change count demonstrated significant discriminative ability for distinguishing between cognitively unimpaired participants and those with questionable impairment (AUC = .621) or mild dementia (AUC = .759). The threshold of two or more declines maintained high specificity (90.1%) for identifying atypical cognitive decline. In a multinomial logistic regression, a change count of two or more was a robust predictor of both questionable impairment (OR = 3.47) and mild dementia (OR = 8.55), beyond the effects of demographic covariates (age, gender, education, race/ethnicity).

CONCLUSIONS: Less than one tenth of cognitively unimpaired older adults show two or more significant declines in their performance on 13 measures from the NACC UDS 3.0 neuropsychological test battery. Individuals who exhibit two or more significant declines in their raw scores across this battery are likely experiencing atypical cognitive decline. Establishing longitudinal base rates of cognitive change across a test battery offers a viable, empirically grounded approach to identifying progression along the dementia continuum.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Chen Z, Zhang B, Liu G, et al (2026)

Systematic Multi-Omics Analysis Reveals Coumestrol as a Dual Modulator of INO80E and LACTB in Alzheimer's Disease.

CNS neuroscience & therapeutics, 32(11):.

OBJECTIVE: To prioritize genetically supported candidate targets for Alzheimer's disease (AD) using an integrative multi-omics framework and to nominate candidate small-molecule compounds with translational potential.

METHODS: Transcriptome-wide association studies (TWAS) were performed by integrating AD genome-wide association study summary statistics with expression quantitative trait locus data from multiple brain regions, whole blood, and single-cell contexts. Multi-marker Analysis of GenoMic Annotation (MAGMA), summary data-based Mendelian randomization (SMR), and Bayesian colocalization analyses were used to further evaluate genetic support for prioritized genes. Single-cell RNA sequencing data from prefrontal cortex samples were analyzed to characterize cell-type expression patterns. Quantitative real-time polymerase chain reaction was conducted in human brain tissues to assess candidate gene expression. Phenome-wide association studies (PheWAS), druggability assessment, and molecular docking were used to explore genetic pleiotropy and nominate candidate compounds. The effects of coumestrol were further examined in PS19-derived primary hippocampal neurons.

RESULTS: Multi-layer TWAS prioritized GIGYF1, LACTB, and INO80E as AD-associated candidate genes, with additional support from MAGMA, SMR, colocalization, single-cell characterization, and human brain tissue validation. PheWAS did not identify broad phenome-wide association signals for LACTB or INO80E in the current dataset. Molecular docking predicted stable interactions between coumestrol and both LACTB and INO80E. In PS19-derived primary hippocampal neurons, coumestrol enhanced cell viability and reduced LACTB and INO80E mRNA expression.

CONCLUSION: This study prioritizes LACTB and INO80E as genetically supported candidate targets for AD and nominates coumestrol as a candidate small molecule requiring further mechanistic and pharmacological validation.

RevDate: 2026-11-16

Chiaravalloti A, Martorana A, Micarelli A, et al (2026)

Cerebello-extracerebellar connectivity and relative FDG uptake in relation to Alzheimer biomarkers and cognitive trajectories.

The neuroradiology journal [Epub ahead of print].

We examined whether a fixed anatomical summary of cerebello-extracerebellar functional connectivity and relative regional fluorodeoxyglucose (FDG) uptake showed convergent associations with Alzheimer biomarkers and subsequent cognition. This exploratory, non-preregistered Alzheimer's Disease Neuroimaging Initiative study averaged 2208 resting-state connections linking 24 cerebellar and 92 extracerebellar regions. A 90-day imaging window yielded 131 participants for global cross-sectional analyses and 126 for regional FDG analyses (123 with complete cerebellar uptake). Four FDG composites used a brainstem reference. Models used heteroscedasticity-robust inference or subject fixed effects with clustered inference for longitudinal clinical and memory trajectories. No principal family survived false-discovery-rate correction: global connectivity, 0/5; regional FDG biomarker, connectivity and longitudinal families, 0/8, 0/4 and 0/8. All 72 regional connectivity and 48 lobular FDG tests were also nonsignificant. Higher tau was nominally associated with lower thalamic uptake (standardized β = -0.231; 95% CI -0.416 to -0.047; p = 0.014; q = 0.114). Additional grey-matter adjustment yielded q = 0.023, a hypothesis-generating sensitivity signal. The findings do not support interpreting these summary measures as compensatory markers in this selected sample. Spatial averaging, limited precision, reference-region dependence, partial-volume effects and linear trajectory assumptions leave smaller, circuit-specific or nonlinear associations unresolved.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Daghini E, Tribble JR, Amato R, et al (2026)

Taurine metabolism: a potential target for neuroprotection in age-related neurodegenerative diseases.

Mammalian genome : official journal of the International Mammalian Genome Society, 38(1):.

Taurine is one of the most abundant free amino acids in mammals and plays essential roles in cellular homeostasis, mitochondrial function, calcium regulation and neuronal survival. Taurine availability varies markedly across tissues, species and sexes, reflecting the balance between endogenous synthesis, dietary intake, transport and efflux. Although reduced taurine levels have been reported in some aging tissues, recent longitudinal studies indicate that circulating taurine does not decline universally with age, and its value as a biomarker of aging remains debated. Alterations in taurine or its transporter SLC6A6 have been described in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease and retinal degenerations. Preclinical studies indicate that taurine supplementation mitigates excitotoxicity, stabilizes mitochondrial function, reduces neuroinflammation and supports myelination and synaptic balance. Despite this strong mechanistic rationale, clinical evidence remains limited and heterogeneous, underscoring the need for biomarker-guided trials and a clearer definition of optimal therapeutic windows. In this review, we summarize the general properties of taurine and its metabolic regulation. We examine taurine's neuroprotective properties across different neurodegenerative conditions and discuss future perspectives for targeting taurine metabolism as a promising but largely unexplored strategy for intervention in age-related neurodegenerative diseases.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Zhang W, Jiang Y, Zhu M, et al (2026)

The emerging role of microglial TREM2 in Alzheimer's Disease: pathogenesis and therapeutic implications.

Molecular biology reports, 53(1):.

Alzheimer's disease (AD), the most common cause of dementia, imposes a substantial and growing burden on families and society. Although AD is classically defined by amyloid and tau pathology, microglial dysfunction is increasingly recognized as a central determinant of disease progression. TREM2 (Triggering Receptor Expressed on Myeloid cells 2), predominantly expressed on microglia, is a key regulator of microglial responses in the AD brain. In this review, we propose that TREM2 functions as a context- and disease-stage-dependent checkpoint that integrates microglial survival, phagocytosis, metabolic adaptation, and inflammatory signaling, thereby shaping AD pathogenesis. This framework helps explain why TREM2 signaling can exert protective or detrimental effects across disease stages and suggests that effective TREM2-directed therapy will require stage-specific modulation rather than simple agonism or inhibition. We critically examine the physiological functions of microglia and TREM2, evaluate TREM2-related biomarkers, and discuss emerging therapeutic strategies, thereby providing a conceptual basis for microglia-targeted AD diagnosis and treatment.

RevDate: 2026-11-16

Chen J, J Tian (2026)

Subcellular proteomics uncovers the link between myelin-axon interface vulnerability and Aβ pathology in Alzheimer's disease.

Science China. Life sciences [Epub ahead of print].

RevDate: 2026-11-16
CmpDate: 2026-11-16

Wang Y, Zhang Y, Wei H, et al (2026)

Integrated Network Toxicology, Machine Learning, and Structural Biology Identify a Candidate Gene Network Linking Predicted Acetyl Tributyl Citrate Targets to Alzheimer's Disease.

Journal of molecular neuroscience : MN, 76(4):.

As a common plasticizer, acetyl tributyl citrate (ATBC) poses a potential public health risk, yet its role in Alzheimer's disease (AD) is unclear. This study seeks to identify candidate molecular links between computationally predicted ATBC targets and AD-associated transcriptional alterations. We combined differential gene expression and co-expression results from two AD-related transcriptomic datasets with in silico ATBC target predictions from ChEMBL, PharmMapper, and SwissTargetPrediction, followed by machine learning feature selection, network toxicology, and molecular docking. We identified sixty-nine overlapping candidate genes shared among AD differentially expressed genes, AD-associated WGCNA modules, and computationally predicted ATBC targets. Among these, three genes-Interferon-stimulated gene 20 kDa (ISG20), Cytochrome P450 26A1 (CYP26A1), and β-1,3-Galactosyltransferase-1 (B3GALT1)-were further prioritized through machine learning. Docking scores were - 5.1 kcal/mol for ISG20, - 5.4 kcal/mol for CYP26A1, and - 4.6 kcal/mol for B3GALT1. These computational results suggest plausible binding poses. Our integrated analysis nominates ISG20, B3GALT1, and CYP26A1 as candidate molecular links between predicted ATBC targets and AD-associated transcriptional changes, providing a computational foundation for experimental validation.

RevDate: 2026-11-16

Bekena S, Singh RK, Pal S, et al (2026)

Sensorimotor impairment and cognitive function across the Alzheimer's disease continuum and major depressive disorder.

GeroScience [Epub ahead of print].

Sensorimotor impairments are associated with cognitive decline, but their cumulative burden across clinical subgroups is not well characterized. To test whether sensorimotor burden is associated with baseline cognition and modifies subgroup-related cognitive differences. We analyzed 511 community-dwelling older adults. Participants were classified as cognitively normal, preclinical Alzheimer's disease (Clinical Dementia Rating score of 0 with amyloid positron-emission tomography positivity), mild cognitive impairment, or major depressive disorder. Cognition was measured with the Preclinical Alzheimer Cognitive Composite. A Sensorimotor Index summed impairments in grip strength, gait speed, reaction time, hearing, vision, and olfaction and was categorized as low (0-1) or elevated (≥ 2). Multivariable linear regression assessed subgroup, index, and subgroup-by-index terms, adjusting for age, sex, race, education, apolipoprotein E ε4 status, and neighborhood deprivation. Without interactions, elevated burden was associated with lower cognitive scores (β =- 0.374; 95% confidence interval, - 0.508 to - 0.240; p < 0.001). In the interaction model, the mild cognitive impairment-by-elevated-index (β =- 0.647; 95% confidence interval, - 0.981 to - 0.313; p < 0.001) and major depressive disorder-by-elevated-index terms (β =- 0.440; 95% confidence interval, - 0.759 to - 0.120; p = 0.007) were significant; the preclinical Alzheimer's disease interaction was not. Dose-response analyses showed progressively lower cognitive scores at higher index levels. Greater sensorimotor burden was associated with lower cognition, with stronger adverse associations in mild cognitive impairment and major depressive disorder. Multidomain sensorimotor assessment may improve characterization of cognitive heterogeneity in older adults.

RevDate: 2026-11-16

Mao E, Lin S, Prasad N, et al (2026)

Design Strategies in Discrete Choice Experiments for Individuals with Cognitive Impairment: A Systematic Review.

The patient [Epub ahead of print].

OBJECTIVES: Patient preference evidence is increasingly important for value assessment and decision making in Alzheimer's disease and related dementias (ADRD). Discrete choice experiments (DCEs) are widely used to elicit patient preferences but may raise feasibility concerns in individuals with cognitive impairment. We aimed to systematically review studies that explicitly evaluated design choices in DCEs for preference elicitation in individuals with cognitive impairment.

METHODS: We systematically searched PubMed, Embase, and CINAHL/PsycINFO through January 23, 2026 for studies that evaluated DCE design adaptations or feasibility in cognitively impaired populations. Findings were synthesized narratively according to adaptations and their reported effects on comprehension, task performance, and respondent burden.

RESULTS: We identified six studies. Four categories of design adaptations were identified: attribute description, simplification of choice task structure, visual design and layout, and survey administration. We learned that attribute familiarity and concreteness improved understanding; respondents struggled when the status-quo state was not anchored to their own current health state. Limiting to three options per task and three attributes per option improved completion rates. Greater overlap in attribute levels across options made tasks easier to complete. Use of icons as illustrations improved attribute comprehension, and caregiver involvement in interviewer-administered surveys aided completion.

CONCLUSIONS: Existing evidence suggests that DCEs can be successfully completed by individuals with mild cognitive impairment or early-stage dementia when tasks are appropriately adapted to lessen complexity. However, the evidence base remains limited. Additional methodological research is needed to identify design strategies that improve accessibility of these tasks to those with cognitive challenges while generating meaningful preference information.

RevDate: 2026-11-16

Ketchum FB, Sanford C, Buckingham W, et al (2026)

Nationwide Geographic Access to Subcutaneous Anti-Amyloid Alzheimer Disease Therapy Infrastructure.

JAMA neurology pii:2856724 [Epub ahead of print].

RevDate: 2026-11-16

Algeciras-Schimnich A, Hu M, Weigand SD, et al (2026)

Absolute Risk of Progression to Cognitive Impairment Based on Plasma Phosphorylated Tau 217, Age, Sex, and APOE ε4.

JAMA neurology pii:2856722 [Epub ahead of print].

IMPORTANCE: Alzheimer disease (AD) pathology can be detected years before symptom onset, but some individuals who are biomarker positive and cognitively unimpaired (CU) remain asymptomatic.

OBJECTIVE: To estimate 5- and 10-year absolute risks of mild cognitive impairment (MCI) and dementia using continuous plasma phosphorylated tau 217 (p-tau217) and p-tau217/amyloid β 42 (Aβ42).

This cohort study included participants from the Mayo Clinic Study of Aging (MCSA) and the Alzheimer's Disease Neuroimaging Initiative (ADNI). Participants were CU individuals aged 60 to 90 years with baseline Fujirebio Lumipulse plasma p-tau217 measurements, APOE genotyping, and longitudinal clinical follow-up. The MCSA is a population-based longitudinal cohort of residents in Olmsted County, Minnesota; ADNI is a multicenter observational cohort. MCSA data were ascertained from October 2008 to September 2025; ADNI data from September 2005 to January 2026.

EXPOSURES: Age, sex, APOE ε4, p-tau217, and p-tau217/Aβ42.

MAIN OUTCOMES AND MEASURES: Transition from CU to MCI and dementia estimated using continuous-time multistate models.

RESULTS: In the MCSA cohort (n = 1644), the median (IQR) age was 72 (66-79) years; 804 participants (49%) were female and 840 (51%) were male. In the ADNI cohort (n = 534), the median (IQR) age was 72 (68-77) years; 297 participants (56%) were female and 237 (44%) were male. A p-tau217 of 0.324 pg/mL vs 0.072 pg/mL (90th vs 10th percentile) was associated with 2.66 (95% CI, 2.02-3.51), 3.02 (95% CI, 2.21-4.12), 2.62 (95% CI, 1.99-3.46), and 2.79 (95% CI, 2.04-3.81) greater hazard of clinical progression in MCSA female participants who did not carry the APOE ε4 variant (ε4-), females who did carry the APOE ε4 variant (ε4+), males who were ε4-, and males who were ε4+, respectively. In ADNI, hazards were 2.67 (95% CI, 1.86-3.85), 2.83 (95% CI, 1.89-4.22), 2.08 (95% CI, 1.48-2.92), and 3.99 (95% CI, 2.59-6.13), respectively. In MCSA, higher baseline p-tau217 and older age were associated with greater absolute risk of progression. At age 75 years and assuming sex and APOE are at the MCSA means of 0.511 and 0.268, 5-year absolute risk of MCI increased from 7% (95% CI, 5%-8%) to 17% (95% CI, 13%-20%) for a p-tau217 concentration of 0.072 vs 0.324 pg/mL; 10-year absolute risk of MCI increased from 15% (95% CI, 12%-18%) to 35% (95% CI, 29%-41%; P < .001 for both). At 0.324 pg/mL, 5-year MCI risk increased from 6% (95% CI, 4%-8%) to 37% (95% CI, 32%-43%) for ages 65 to 85 years; 10-year risks were 17% (95% CI, 12%-21%) and 66% (95% CI, 57%-74%; P < .001 for both). Results were similar for p-tau217/Aβ42.

CONCLUSIONS AND RELEVANCE: This study found that higher plasma p-tau217 and older age were associated with higher 5- and 10-year risk of cognitive impairment. Plasma p-tau217 concentrations, combined with age, sex, and APOE ε4 status, can enable individualized estimation of short-term absolute risk of cognitive impairment in CU individuals, with applications in prognosis and trial enrichment in preclinical AD.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Bayart JL, Villain N, Planche V, et al (2026)

Robustness of Plasma P-Tau217 Diagnostic Thresholds for Alzheimer Disease Across Various Clinical Populations and Laboratory Environments.

Neurology, 107(11):e218784.

BACKGROUND AND OBJECTIVES: Blood-based biomarkers (BBMs), especially plasma tau phosphorylated at threonine 217 (p-tau217), could scale Alzheimer disease (AD) clinical-biological diagnosis, but clinical use requires thresholds transferable across laboratories and populations. We compared Lumipulse p-tau217 with other BBMs; evaluated amyloid-anchored thresholds across centers, analyzers, reagent lots, and clinical populations; and assessed second-line CSF adjudication of gray zone results.

METHODS: This multicenter, cross-sectional diagnostic-classification study included an exploratory Brussels cohort and 3 external validation cohorts. Brussels participants were cognitively unimpaired or impaired and had Aβ status determined by amyloid-PET or CSF Aβ42 and tau status by tau-PET or CSF p-tau181. Validation cohorts comprised consecutive Paris memory-clinic patients, patients with early-onset neurodegenerative dementia in Bordeaux, and individuals with monogenic frontotemporal lobar degeneration (FTLD). Plasma p-tau217 was measured locally on Lumipulse analyzers. BBMs and ratios were compared using receiver operating characteristic (ROC) analyses. In Brussels, a Youden cutoff and dual 95% or 97.5% sensitivity/specificity cutoffs were derived; intermediate values defined gray zones.

RESULTS: Among 411 participants (mean age 70.5 years; 51.6% female), p-tau217 showed the best diagnostic performance; p-tau217/Aβ42 did not improve performance or reduce gray zones. In Brussels, p-tau217 discriminated Aβ+ from Aβ- status (AUC 0.96, 95% CI 0.93-0.98; p < 0.0001). The 0.193 pg/mL Youden cutoff (95% CI 0.178-0.213) yielded 91.5% sensitivity (95% CI 84.7-95.5) and 91.6% specificity (95% CI 84.8-95.5) and detected neocortical tau-PET positivity with 98.5% sensitivity and 81.8% specificity. In Paris, sensitivity/specificity for clinical-biological AD were 93.2% (95% CI 85.1-97.1)/93.0% (95% CI 81.4-97.6); in Bordeaux, sensitivity/specificity for clinical-biological AD were 95.7% (95% CI 79.0-99.2)/92.3% (95% CI 66.7-98.6). Specificity in monogenic FTLD was 88.4% (95% CI 75.5-94.9). False-positive classifications were enriched in FTLD with amyotrophic lateral sclerosis (ALS). Dual thresholds yielded gray zones in 15.4%-24.8% of Paris patients; second-line CSF testing resolved 86.2%-88.9% of gray zone cases.

DISCUSSION: Lumipulse plasma p-tau217 thresholds were transferable across centers, analyzers, reagent lots, and heterogeneous clinical populations, supporting evaluation of plasma-first pathways with confirmatory testing for gray zone values. Values below 0.193 pg/mL made neocortical tauopathy unlikely. Limitations include cross-sectional design, specialized Western European recruitment, unavailable race/ethnicity data, heterogeneous reference standards, incomplete AD copathology adjudication in monogenic FTLD, and no cross-platform comparison.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Weber SK, Farris CM, Ma Y, et al (2026)

Identification of Type 1 and Type 2 α-Synuclein-Seeds by CSF Seed Amplification Assay in Patients With Movement Disorders.

Neurology, 107(11):e218763.

BACKGROUND AND OBJECTIVES: A novel α-synuclein (syn) seed amplification assay (synSAA) differentiates 2 types of syn-seeds in CSF: type1, associated with Lewy bodies (LBs), and type2, associated with glial-cytoplasmic inclusions, the hallmark of multiple system atrophy (MSA). However, syn-copathology extends beyond synucleinopathies, and copathologies are increasingly relevant. Different syn-seeds have been assessed in highly characterized research cohorts, but data assessing type and frequency in patients from routine clinical encounters are lacking. Hence, our objective was to determine frequency, type, and clinical association of different syn-seeds in CSF in a large cohort from a movement disorders (MDs) clinic.

METHODS: This cross-sectional study included consecutive patients from a MD clinic between 2009 and 2025. CSF was tested with synSAA and clinical data derived from medical records.

RESULTS: We recruited 1,059 patients (mean age 70.5 ± 10.5 years; 38.4% female; mean disease duration 4.0 ± 4.6 years). Syn-seeds were detected in 54.2% of patients, with type1-seeds predominating (88.5%). High synSAA positivity was observed in Parkinson disease (PD) (84.7%), dementia with LB (93.4%), MSA (84.5%), isolated REM-sleep behavior disorder (iRBD) (80.0%), and normal pressure hydrocephalus (NPH) with PD (87.0%). Undetermined hypokinetic MD showed 53.7% positivity. Moderate proportions (∼25-33%) were detected in Alzheimer disease, progressive supranuclear palsy (PSP), corticobasal syndrome, and idiopathic NPH without PD, while other neurologic disorders showed 20.9% positivity. Type2-seeds were the major seed type in MSA (79.6% of syn-seeds) and minor type in PD (6.2%), PSP (9.1%), and undetermined hypokinetic MD (13.8%). Overall, type2-seeds were present in only 2.6% of non-MSA patients. Patients with type1-seeds had worse olfaction and more hallucinations. Multivariable regression identified impaired olfaction (OR = 0.67 per point increase of identified smells out of 12, higher scores indicating better olfaction) significantly associated with type1-seeds.

DISCUSSION: Our results provide reference data on syn-seed frequency in routine clinical patients, demonstrating that type1-seeds indicate common underlying syn-pathology or copathology associated with hyposmia and hallucinations. Type2-seeds are specific to MSA and detection of type2-seeds outside the clinical MSA spectrum can improve diagnosis of patients with atypical presentations because our results match neuropathologic MSA studies. In vivo identification of different seed types will improve diagnosis, clinical trial stratification, and development of targeted therapies.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Pezzoli S, Oddi AP, Blazhenets G, et al (2026)

APOE Genotype and Amyloid PET in People With Mild Cognitive Impairment or Dementia: Results from Clinical Practice.

Neurology, 107(11):e218689.

BACKGROUND AND OBJECTIVES: APOE genotype is the strongest genetic risk factor for sporadic Alzheimer disease, but evidence on its utility in clinical practice is limited. We evaluated the predictive value of APOE genotype for PET-measured amyloid positivity and global amyloid burden in older adults with cognitive impairment evaluated in memory clinics as part of their clinical care. We also examined associations between APOE genotype and clinical presentation, including impairment level (mild cognitive impairment [MCI] or dementia) and MCI type (amnestic or nonamnestic).

METHODS: This observational multicenter study included Medicare beneficiaries with MCI or dementia from the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) study, who were coenrolled in the Amyloid Neuroimaging and Genetics Initiative (ANGI). Participants underwent amyloid PET and APOE genotyping. Amyloid status was determined using local visual reads and a Centiloid threshold (24.4). Logistic regression assessed associations between APOE genotype and amyloid positivity. Analysis of covariance models assessed differences in global amyloid burden (Centiloids) across genotypes. Voxel-wise analyses examined regional tracer uptake.

RESULTS: The study included 1,641 participants (mean [SD] age, 74.3 [5.6] years; 43.6% female), of whom 1,219 had MCI and 422 had dementia. APOE2/4, APOE3/4, and APOE4/4 genotypes had progressively higher odds of visual reads-based amyloid positivity compared with APOE3/3 (APOE2/4, OR = 3.10, 95% CI [1.58-6.47], p = 0.002; APOE3/4, OR = 4.52, 95% CI [3.50-5.86], p < 0.001; APOE4/4, OR = 26.34, 95% CI [12.93-63.39], p < 0.001). The results were similar when scan positivity was defined by a Centiloid threshold. Amyloid burden increased progressively across APOE genotypes, with higher-risk genotypes (APOE3/4 and APOE4/4) showing the highest Centiloids (p < 0.001, partial η[2] = 0.20). Among amyloid-positive participants, APOE4 genotype was associated with increased tracer uptake across posterior cingulate, precuneus, medial frontal, temporoparietal, and lateral frontal cortices in a dose-dependent manner, whereas APOE2 genotype showed a more focal distribution. A significant APOE3/4-by-sex interaction indicated higher odds of visual reads-based amyloid positivity in APOE3/4 women. Clinically, APOE4/4 was associated with dementia and amnestic MCI.

DISCUSSION: APOE4 genotype was associated with both amyloid PET positivity and quantitative amyloid burden, following a dose-dependent gradient. These findings extend evidence linking APOE genotype to amyloid pathology in clinical settings. Limitations include restriction to cognitively impaired individuals and limited racial and ethnic diversity.

RevDate: 2026-11-16
CmpDate: 2026-11-16

Aali A, Schaffner S, Lam JST, et al (2026)

The Burden of Neurologic Disorders in Canada, 1990-2023: A Systematic Analysis in the Global Burden of Disease Study 2023.

Neurology, 107(11):e218702.

BACKGROUND AND OBJECTIVES: Neurologic disorders are leading contributors to global disability and mortality, yet Canada-specific burden estimates have not been updated with the most recent Global Burden of Disease (GBD) data. We aimed to quantify the burden of 18 neurologic conditions in Canada in 2023, characterize trends from 1990 to 2023, describe age-specific and sex-specific patterns, and compare Canada with the high-income country average.

METHODS: This retrospective epidemiologic modeling study analyzed GBD 2023 data for Canada. Eighteen conditions whose primary health loss manifestation directly affects the central or peripheral nervous system were included. Outcome measures included prevalence, mortality, and disability-adjusted life years (DALYs) comprising years lived with disability (YLDs) and years of life lost (YLL). Age-standardized rates are all per 100,000 population. 95% uncertainty intervals (UI) are reported for all estimates.

RESULTS: Modeling evaluated the entire Canadian population across 34 years. In 2023, neurologic disorders accounted for 11.48% (UI: 9.47-14.26) of total DALYs and 16.31% (UI: 10.56-26.24) of deaths. Burden was heavily driven by nonfatal disability metrics (YLDs); Alzheimer disease and other dementias led absolute DALYs at 366,548.5 (UI: 180,491.8-710,281.4), followed by migraine at 232,619.5 (UI: 151,390.4-320,391.1) and ischemic stroke at 223,748.0 (UI: 194,981.3-249,309.6). Migraine led age-standardized DALY rates at 565.8 (UI: 374.0-783.1) per 100,000, driven entirely by nonfatal disability metrics. Dementias drove mortality with 20,108.6 (UI: 4,999.6-50,266.6) deaths. From 1990 to 2023, the steepest age-standardized DALY rate increases occurred in other neurologic disorders (153.6% [UI: 129.0-185.1]), encephalitis (59.2% [UI: 25.1-95.6]), and Parkinson disease (25.4% [UI: 18.9-33.0]), while meningitis declined by 62.6% (UI: 57.4-66.9).

DISCUSSION: Neurologic disorders present a substantial public health challenge in Canada, marked by widespread midlife nonfatal disability from migraine and escalating late-life neurodegeneration. Over 3 decades, the national burden shifted toward chronic neurodegenerative diseases. These findings highlight the need for national strategies to expand care capacity and address chronic disability. A key limitation of this analysis is that GBD estimates for Canada are currently restricted to the national level; because Canada is a vast, geographically and demographically diverse nation, country-wide aggregates do not elucidate critical subnational disparities.

RevDate: 2026-11-16

Pichet Binette A (2026)

From Research Cohorts to Clinical Practice: Bringing Alzheimer Disease Genetic and Biomarker Discoveries Into the Memory Clinic.

Neurology, 107(11):e218748.

RevDate: 2026-11-16

Li X, Xu H, Zhang Y, et al (2026)

Cellular Senescence and White-Matter Injury: A Proposed Glial Cascade in AD and Cerebral SVD.

Aging and disease pii:AD.2026.1063 [Epub ahead of print].

Cellular senescence is one of the hallmarks of aging and has been implicated in age-related neurological disorders, including Alzheimer's disease (AD) and cerebral small-vessel disease (SVD). AD and SVD frequently coexist and both become more common with age, so an age-dependent mechanism may contribute to both. Although their upstream pathologies differ, both can damage white matter. This review proposes a cascade in which microglial senescence may sustain inflammation in white matter and impair myelin debris clearance. In this environment, oligodendrocyte precursor cells (OPCs) may differentiate poorly, limiting remyelination, while senescence-like changes within these cells may compound this deficit. Senescent brain endothelial cells may also damage white matter through blood-brain barrier disruption, microvascular rarefaction, reduced perfusion, and impaired neurovascular coupling. Because barrier leakage activates microglia and poor perfusion may limit metabolic support to the oligodendrocyte lineage, these vascular changes could aggravate glial dysfunction. This review integrates evidence scattered across different models and diseases, examining each link in the proposed cascade in turn. The full sequence has not yet been demonstrated in a single experimental system or in humans. In animal models, eliminating or modulating senescent cells has improved pathology or cognition, and restoring aged OPC function has enhanced remyelination. In people, senolytic trials have assessed safety and drug exposure but have not yet established clinical benefit. White-matter injury may serve as a measurable endpoint shared by AD and SVD, and cellular senescence remains a potential contributor to this injury.

RevDate: 2026-11-16

Wang X, Lv A, Tian Y, et al (2026)

The Microglial Lipid-Immune Axis in Brain Aging: Adaptive Lipid Handling and Metabolic Dysfunction in Lipid-Droplet-Accumulating Microglia.

Aging and disease pii:AD.2026.1294 [Epub ahead of print].

Microglia in the aging brain process lipids released during membrane and myelin turnover. Lipid droplets can buffer this demand, but lipid retention also accompanies defective phagocytosis and inflammatory responses. This review critically compares the substrates, perturbations, and functional endpoints underlying these observations. We examine cholesterol esterification and export, fatty-acid activation and triacylglycerol synthesis, and lipid mobilization through lipolysis and lipophagy in relation to TREM2-TYROBP/DAP12-SYK signaling, APOE genotype, and local substrate supply. Physiological-aging studies are distinguished from demyelination, Alzheimer's disease, and Parkinson's disease models. Quantitative comparisons show why inhibiting storage can improve selected amyloid-associated phenotypes while impaired storage can compromise myelin repair. We use the established distinction between lipid pools and metabolic flux to assess what each experiment demonstrates: altered droplet abundance, a specific processing defect, or recovery of a cellular task. We propose a reporting framework covering droplet burden, transcriptional state, metabolic function, and cellular performance, with missing measurements retained explicitly and no claim of validated diagnostic thresholds. Intervention evidence is assessed by the reaction perturbed, dose and duration, target validation, delivery route, and measured benefit. The resulting synthesis identifies supported mechanisms and unresolved causal steps, providing a practical basis for selecting and evaluating interventions without treating droplet reduction as a universal therapeutic endpoint.

RevDate: 2026-11-16

Zhang W, Hu Q, Ding M, et al (2026)

Toward Closed-Loop Cognitive Modulation in Alzheimer's Disease: BCI-Relevant Evidence and a Translational Roadmap.

Aging and disease pii:AD.2026.11026 [Epub ahead of print].

Alzheimer's disease (AD) has entered a biomarker-defined era, yet most cognitive and neuromodulatory interventions continue to use fixed targets, timing, and doses. This targeted narrative review maps brain-computer interface (BCI) and closed-loop-relevant evidence in AD and mild cognitive impairment (MCI) by examining how sensing, control, and intervention modules are used prospectively. Read modules include electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), real-time functional magnetic resonance imaging (fMRI), functional ultrasound (fUS) and transcranial ultrasound localization microscopy (t-ULM), and digital measures. Control functions include feature extraction, within-person state decoding, uncertainty-aware decision rules, target-engagement assessment, and safety oversight. Write modules include neurofeedback, sensory gamma and sleep-phase acoustic stimulation, transcranial alternating-current stimulation (tACS), transcranial direct-current stimulation (tDCS), repetitive transcranial magnetic stimulation (rTMS), transcranial pulse stimulation (TPS), transcranial ultrasound stimulation (TUS), transcranial photobiomodulation (tPBM), and focused ultrasound-mediated blood-brain barrier (FUS-BBB) opening. Human studies have separately demonstrated signal-contingent feedback, individualized targeting, physiological target engagement, home delivery, and emerging sensing, while preclinical studies provide mechanistic support for gamma, optical, and ultrasound approaches. Sleep-phase acoustic stimulation additionally demonstrates early automated signal-to-stimulus control. Passive sensing provides observations, personalization sets baseline parameters, state-informed control uses current signals to alter delivery, and target engagement verifies the proximal response without establishing clinical efficacy. Reliable decoding of waking cognitive states, broader controller utility, and durable clinical benefit remain unvalidated. We therefore organize the field around disease context, state sensing, feature extraction, state decoding, bounded decision/intervention, response verification, and safety oversight. The decisive early design compares assignments to an adaptive policy with otherwise matched fixed delivery; a sham arm can additionally test intervention efficacy. Such trials must prespecify decoder calibration, uncertainty, abstention, safety limits, and mechanistic and clinical endpoints. Closed-loop cognitive modulation therefore defines a translational research agenda for AD.

RevDate: 2026-11-16

Brum WS, Janelidze S, Singh A, et al (2026)

A Plasma eMTBR-Tau Immunoassay for Detection of Advanced Insoluble Tau Pathology.

JAMA pii:2856953 [Epub ahead of print].

IMPORTANCE: Blood biomarkers that reflect neurofibrillary tau burden, a defining hallmark of Alzheimer disease (AD), remain limited. Endogenously cleaved microtubule-binding region tau 243 (eMTBR-tau243) has shown promise when measured by mass spectrometry; a scalable immunoassay could broaden research access and support clinical evaluation.

OBJECTIVE: To determine whether plasma levels of eMTBR-tau measured by a novel immunoassay are associated with tau neurofibrillary tangle pathology defined by neuropathology and tau positron emission tomography (PET).

This cross-sectional study included brain donors with antemortem plasma from 2 US autopsy cohorts, and individuals with plasma samples and tau PET from 2 imaging cohorts in Canada and Sweden, with visits between 2002 and 2025 depending on the cohort.

EXPOSURES: Plasma eMTBR-tau measured with an immunoassay and eMTBR-tau243 measured with mass spectrometry.

MAIN OUTCOMES AND MEASURES: Plasma eMTBR-tau levels across neuropathologic Braak neurofibrillary tangle stages (I-VI, ranging from tangles confined to the entorhinal region to widespread neocortical tangles) and tau-PET Braak stages (0-VI), expressed as fold changes. Correlations with regional tau-PET standardized uptake value ratios (SUVRs; higher values indicating more tau tangles), discrimination of regional tau-PET positivity (area under the curve [AUC]), and correlation with mass spectrometry-based eMTBR-tau243.

RESULTS: The study included 728 participants in 4 cohorts (median age by cohort, 71.0-83.5 years; 41.3%-56.6% female). In the 2 autopsy cohorts (n = 241 and n = 240), eMTBR-tau age- and sex-adjusted geometric means were 0.0021 pg/mL and 0.0040 pg/mL, respectively, at Braak stages I-II vs 0.107 pg/mL and 0.101 pg/mL at Braak stage VI (50.5-fold [95% CI, 26.3-97.0] and 25.2-fold [95% CI, 15.8-40.3] higher for stage VI vs stages I-II; P < .001 for both cohorts). In one imaging cohort (n = 99), compared with tau-PET Braak stage 0, eMTBR-tau levels were 11.0-fold (95% CI, 6.9-17.5) higher at stages III-IV and 59.9-fold (95% CI, 39.5-90.7) higher at stages V-VI. Among participants positive for amyloid-β (Aβ) in another imaging cohort (n = 50), the Spearman rank correlations for eMTBR-tau with tau-PET SUVRs were ρ = 0.52 (95% CI, 0.28-0.70) in Braak regions I-II, 0.76 (95% CI, 0.61-0.86) in regions III-IV, and 0.85 (95% CI, 0.75-0.91) in regions V-VI (all P < .001). Immunoassay and mass spectrometry measurements were strongly correlated (Spearman rank correlation, ρ = 0.93 in all participants [n = 108] and ρ = 0.96 in Aβ-positive participants [n = 54]) and discriminated tau-PET positivity similarly (n = 102; AUC range, 0.96-0.99 for the immunoassay and 0.97-0.99 for mass spectrometry).

CONCLUSIONS AND RELEVANCE: A plasma eMTBR-tau immunoassay identified neocortical tau pathology in autopsy and tau-PET cohorts and correlated strongly with mass spectrometry measurements, a proof of principle that eMTBR-tau can be measured by immunoassay as a marker of advanced neurofibrillary tangle pathology.

RevDate: 2026-11-16

Tran SD, Yoon HJ, Gahm JK, et al (2026)

ASAM: Adaptive cortical surface representation via dynamic local aggregation and hybrid Attention-Mamba global modeling.

Medical image analysis, 116:104394 pii:S1361-8415(26)00463-9 [Epub ahead of print].

Accurately modeling cortical surface geometry from structural MRI is essential for advancing neuroimaging analysis and biomarker discovery. Recent advances in Transformer and Mamba architectures have shown promise in brain surface modeling by effectively capturing complex feature dependencies. However, they typically rely on fixed or absent neighborhood structures, substantially limiting their ability to represent localized cortical variations. Transformers also incur high computational costs, whereas Mamba lacks explicit mechanisms for encoding local spatial context on non-Euclidean domains. To address these limitations and leverage the complementary strengths of both architectures, we propose ASAM (Adaptive Surface representation with Attention and Mamba), a hybrid framework integrating Transformer and Mamba mechanisms within a parallel architecture. ASAM introduces two novel modules designed specifically for cortical surfaces: Dynamic Multi-Hop Selection (DMHS), which adaptively determines optimal receptive fields for each cortical patch, and Dynamic Feature Merging (DFM), which constructs context-sensitive adjacency matrices from geodesic distances and learned affinities. Extensive evaluations on public neuroimaging datasets demonstrate that ASAM achieves superior or highly competitive performance compared to state-of-the-art Transformer- and Mamba-based baselines in CN vs. MCI classification on ADNI and cross-dataset brain age prediction. By dynamically adjusting neighborhood scales, ASAM yields enriched, geometry-aware cortical surface representations, supporting neuroimaging research on risk stratification and developmental brain assessments while motivating further multi-center validation toward clinical translation. Implementation code is publicly available at: https://github.com/sydat2701/ASAM_surface.git.

RevDate: 2026-11-16

Xu K, He X, Zhang T, et al (2026)

Discovery of multifunctional coumarin-benzylpiperidine hybrids combining acetylcholinesterase inhibition with attenuation of tau hyperphosphorylation for Alzheimer's disease.

European journal of medicinal chemistry, 322:119535 pii:S0223-5234(26)00980-3 [Epub ahead of print].

Alzheimer's disease (AD) arises from complex multifactorial pathologies, highlighting the potential of multifunctional agents for therapeutic intervention. Herein, 42 coumarin-benzylpiperidine hybrids were designed and synthesized to integrate acetylcholinesterase (AChE) inhibition with modulation of tau-associated pathology. The lead compound KZ18 exhibited potent AChE inhibitory activity against eeAChE (IC50 = 0.148 μM) and hAChE (IC50 = 0.105 μM). Molecular docking suggested a binding mode spanning the catalytic active site and peripheral anionic site of AChE. KZ18 was classified as CNS+ in the experimental PAMPA-BBB assay. In okadaic acid-challenged SH-SY5Y cells, KZ18 improved cell viability, reduced intracellular reactive oxygen species accumulation, and attenuated tau phosphorylation at Ser202/Thr205 and Ser396, accompanied by restoration of GSK3β Ser9 phosphorylation. Moreover, oral administration of KZ18 ameliorated scopolamine-induced deficits in spatial working memory, learning, and memory retention, while attenuating hippocampal neuronal damage and astrocyte reactivity. These findings identify KZ18 as a potential multifunctional lead for further anti-AD drug development.

RevDate: 2026-11-16

Rezaei Z, Torabi R, Ryait H, et al (2026)

Foraging reveals systematic suboptimality that is amplified in a mouse model of Alzheimer disease.

Behavioural brain research pii:S0166-4328(26)00547-4 [Epub ahead of print].

Adaptive decision-making extends beyond selecting among discrete alternatives. It requires the dynamic organization of actions as costs, opportunities, and goals evolve over time. Foraging captures this complexity in an evolutionarily conserved behavior that integrates spatial, temporal, and reward-related information across successive actions. These demands make foraging an ecologically grounded framework for investigating Alzheimer disease, in which spatial cognition, temporal organization, cost evaluation, and behavioral flexibility are frequently disrupted. We examined foraging-related action selection in control C57BL/6J mice and APP[NL-G-F] knock-in mice using a controlled task in which travel distance, food texture, and pellet size altered the costs and benefits of available strategies. Bayesian multinomial modeling showed that control mice flexibly redistributed their behavior across conditions, whereas APP[NL-G-F] mice showed impaired cost integration, increased withdrawal, and reduced behavioral flexibility rather than a generalized performance impairment. Comparison with a classical reward-rate-maximization benchmark revealed substantial suboptimality in both groups. Control mice selected the rate-maximizing behavior on 53% of trials, compared with 45% in APP[NL-G-F] mice and exhibited lower regret. These systematic departures suggest that behavior was shaped by cognitive, motivational, or contextual constraints not represented in the normative model, with Alzheimer-disease-relevant dysfunction associated with greater suboptimality. Group differences were greatest when optimal behavior was highly sensitive to competing costs. By preserving the distribution of behavior across strategies, this study establishes foraging-related action selection as a framework for detecting disease-associated disruptions that may be obscured by conventional measures of choice or overall task performance.

RevDate: 2026-11-16

Zhou T, Xu Y, Zhou Q, et al (2026)

RVG29-modified reduction-responsive nanomicelles for brain-targeted delivery of a glutaminyl cyclase inhibitor in Alzheimer's disease.

International journal of pharmaceutics pii:S0378-5173(26)01143-9 [Epub ahead of print].

Although glutaminyl cyclase (QC)-mediated formation of pyroglutamate-modified amyloid-β (pE-Aβ) has been implicated as an upstream pathological event in Alzheimer's disease (AD), the therapeutic translation of small-molecule QC inhibitors remains limited by insufficient brain exposure. Here, we developed a reduction-responsive polymeric micellar platform (designated PIC) based on poly(ethylene glycol) (PEG)-poly(aspartic acid) (PAsp)-poly(valine) (PVal) copolymers. This platform was functionalized with rabies virus glycoprotein-derived peptide 29 (RVG29) to obtain RVG29-PIC-B13 for enhanced brain delivery of B13, an imidazole-based QC inhibitor, and release of its active thiol form. B13 was conjugated to PEG-PAsp-PVal micelles through a disulfide linker, whereas RVG29 was introduced as a brain-targeting ligand to enhance blood-brain barrier transport. RVG29-PIC-B13 formed spherical nanomicelles with an average diameter of 169.9 nm, a drug-loading content of 6.2%, high colloidal stability, and glutathione-triggered release of B13-SH, which retained QC inhibitory activity with an IC50 of 1.17 μM. RVG29 modification significantly enhanced cellular uptake in bEND.3, PC12, and SH-SY5Y cells, increased transport across a bEND.3 monolayer by 3.12-fold, and elevated brain fluorescence accumulation in vivo by 2.58-fold and 1.96-fold compared with free Cy5 and unmodified micelles, respectively. In 8-month-old 3 × Tg-AD mice, 45-day administration of RVG29-PIC-B13 significantly improved performance in the Morris water maze, Y-maze, open-field, and elevated plus maze assays. Mechanistically, RVG29-PIC-B13 inhibited brain QC activity without markedly altering QC expression, reduced Aβ and pE-Aβ burden, attenuated AT8/AT100-associated tau phosphorylation, and preserved dendritic complexity and spine density. Preliminary hematological and histological analyses indicated acceptable biocompatibility. These findings support RVG29-PIC-B13 as a promising reduction-responsive nanodelivery strategy for enhancing brain delivery of QC inhibitors and improving therapeutic outcomes in AD.

RevDate: 2026-11-14

Huang J, Wan H, Jiang W, et al (2026)

EEG Microstate Alterations and Their Association with Cognitive Performance in Late-Onset Epilepsy of Unknown Etiology: Comparison with Alzheimer's Disease.

Brain research bulletin pii:S0361-9230(26)00507-1 [Epub ahead of print].

BACKGROUND: Cognitive impairment is common in late-onset epilepsy of unknown etiology (LOEU), but its electrophysiological correlates and relationship to Alzheimer's disease (AD) remain unclear. We compared resting-state electroencephalogram (EEG) microstate dynamics among LOEU, AD, and cognitively normal (CN) groups and examined their associations with cognitive performance.

METHODS: Eyes-closed 32-channel resting-state EEG recordings were analyzed from 60 patients with LOEU, 65 with AD, and 60 CN participants. Four canonical microstate classes (A-D) were identified. Group differences in microstate parameters were tested with false discovery rate correction. Associations with Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) scores were examined using multivariable interaction models adjusted for age, sex, education, and cerebral small vessel disease burden.

RESULTS: Microstate B duration was longer in LOEU and AD than in CN (Holm-adjusted p=0.011 and 0.016), whereas microstate C occurrence was lower in both patient groups (p=0.001 and 0.018). Microstate D duration was longer in LOEU than in CN and AD (both p=0.038). For microstate A duration, the group interaction survived false discovery rate correction for MMSE (q=0.0255) but not MoCA (q=0.122). In LOEU, longer microstate A duration was associated with lower MoCA and MMSE scores. Pairwise slope comparisons were more negative in LOEU than in CN for both outcomes, whereas LOEU-AD slope differences were not significant.

CONCLUSIONS: LOEU showed altered resting-state EEG microstate dynamics that partly overlapped with those observed in AD, alongside a group difference in microstate D duration. Microstate A duration was associated with cognitive performance in LOEU, although this association did not significantly differ from that observed in AD. These findings support further investigation of EEG microstates as electrophysiological correlates of cognitive dysfunction in LOEU while also highlighting overlap with AD.

RevDate: 2026-11-14

Lee EY, Park J, Lee J, et al (2026)

DEGORA: turning heterogeneous published DEG summaries into an inspectable gene-evidence atlas.

Methods (San Diego, Calif.) pii:S1046-2023(26)00227-6 [Epub ahead of print].

Published tables of differentially expressed genes (DEG tables) can support secondary transcriptomic analyses when expression matrices or variance estimates are unavailable, but they are not consistently deposited in public repositories. DEGORA converts curated DEG tables into a local database that links gene-level evidence to original studies. It standardizes gene identifiers, collapses related contrasts within studies so that each study contributes once, applies fixed heuristic quality weights, and ranks genes by cross-study support and directional concordance. An optional search module identifies potentially reusable tables. We evaluated DEGORA using four human transcriptional programs as positive-control benchmarks, each represented by 2 to 15 publication-level source units and by up to 20 after human microarray sources were added. DEG tables for three programs were generated from publicly available count matrices, whereas those for the fourth were obtained from the original publications. Using RNA-seq evidence, DEGORA recovered 93% of interferon, 59% of endoplasmic reticulum stress, 73% of heat-shock, and 85% of hypoxia markers among the top 100 ranked genes. In three confirmatory datasets, DEGORA showed no consistent ranking advantage over alternative methods applied to the same tables. The same workflow organized published Alzheimer's disease cohort evidence without recomputing differential expression. Across ten evaluated datasets, performance varied with how the input tables were generated. Overall, DEGORA organizes differential expression evidence at the study level and keeps every ranked gene linked to the publications, assays, and reported statistics behind it.

▼ ▼ LOAD NEXT 100 CITATIONS

RJR Experience and Expertise

Researcher

Robbins holds BS, MS, and PhD degrees in the life sciences. He served as a tenured faculty member in the Zoology and Biological Science departments at Michigan State University. He is currently exploring the intersection between genomics, microbial ecology, and biodiversity — an area that promises to transform our understanding of the biosphere.

Educator

Robbins has extensive experience in college-level education: At MSU he taught introductory biology, genetics, and population genetics. At JHU, he was an instructor for a special course on biological database design. At FHCRC, he team-taught a graduate-level course on the history of genetics. At Bellevue College he taught medical informatics.

Administrator

Robbins has been involved in science administration at both the federal and the institutional levels. At NSF he was a program officer for database activities in the life sciences, at DOE he was a program officer for information infrastructure in the human genome project. At the Fred Hutchinson Cancer Research Center, he served as a vice president for fifteen years.

Technologist

Robbins has been involved with information technology since writing his first Fortran program as a college student. At NSF he was the first program officer for database activities in the life sciences. At JHU he held an appointment in the CS department and served as director of the informatics core for the Genome Data Base. At the FHCRC he was VP for Information Technology.

Publisher

While still at Michigan State, Robbins started his first publishing venture, founding a small company that addressed the short-run publishing needs of instructors in very large undergraduate classes. For more than 20 years, Robbins has been operating The Electronic Scholarly Publishing Project, a web site dedicated to the digital publishing of critical works in science, especially classical genetics.

Speaker

Robbins is well-known for his speaking abilities and is often called upon to provide keynote or plenary addresses at international meetings. For example, in July, 2012, he gave a well-received keynote address at the Global Biodiversity Informatics Congress, sponsored by GBIF and held in Copenhagen. The slides from that talk can be seen HERE.

Facilitator

Robbins is a skilled meeting facilitator. He prefers a participatory approach, with part of the meeting involving dynamic breakout groups, created by the participants in real time: (1) individuals propose breakout groups; (2) everyone signs up for one (or more) groups; (3) the groups with the most interested parties then meet, with reports from each group presented and discussed in a subsequent plenary session.

Designer

Robbins has been engaged with photography and design since the 1960s, when he worked for a professional photography laboratory. He now prefers digital photography and tools for their precision and reproducibility. He designed his first web site more than 20 years ago and he personally designed and implemented this web site. He engages in graphic design as a hobby.

963 Red Tail Lane
Bellingham, WA 98226

206-300-3443

E-mail: RJR8222@gmail.com

Collection of publications by R J Robbins

Reprints and preprints of publications, slide presentations, instructional materials, and data compilations written or prepared by Robert Robbins. Most papers deal with computational biology, genome informatics, using information technology to support biomedical research, and related matters.

Research Gate page for R J Robbins

ResearchGate is a social networking site for scientists and researchers to share papers, ask and answer questions, and find collaborators. According to a study by Nature and an article in Times Higher Education , it is the largest academic social network in terms of active users.

Curriculum Vitae for R J Robbins

short personal version

Curriculum Vitae for R J Robbins

long standard version

RJR Picks from Around the Web (updated 11 MAY 2018 )